<SEC-DOCUMENT>0001493152-25-011367.txt : 20250724
<SEC-HEADER>0001493152-25-011367.hdr.sgml : 20250724
<ACCEPTANCE-DATETIME>20250724080048
ACCESSION NUMBER:		0001493152-25-011367
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20250724
DATE AS OF CHANGE:		20250724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Azitra, Inc.
		CENTRAL INDEX KEY:			0001701478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				464478536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-288766
		FILM NUMBER:		251144564

	BUSINESS ADDRESS:	
		STREET 1:		21 BUSINESS PARK DRIVE, SUITE 6
		CITY:			BRANFORD
		STATE:			CT
		ZIP:			06405
		BUSINESS PHONE:		(203) 489-0183

	MAIL ADDRESS:	
		STREET 1:		21 BUSINESS PARK DRIVE, SUITE 6
		CITY:			BRANFORD
		STATE:			CT
		ZIP:			06405

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Azitra Inc
		DATE OF NAME CHANGE:	20170320
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>form424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(3)</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-288766 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to 2,245,968 Shares of Common Stock Underlying the Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b3_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the offering and resale by the selling stockholders identified herein (the &ldquo;Selling Stockholders&rdquo;)
of up to 2,245,968 shares (the &ldquo;Warrant Shares&rdquo;) of our common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;)
issuable upon exercise of Common Stock purchase warrants (the &ldquo;Warrants&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants were issued and sold to the Selling Stockholders pursuant to the letter agreement, dated February 6, 2025, that we entered into
with the Selling Stockholders (the &ldquo;Letter Agreement&rdquo;). See &ldquo;The February Transactions&rdquo; section of this prospectus
for a description of the Letter Agreement and the &ldquo;Selling Stockholders&rdquo; section of this prospectus for additional information
regarding the Selling Stockholders. The prices at which the Selling Stockholders may resell the Warrant Shares offered hereby will be
determined by the prevailing market price for the Common Stock or in negotiated transactions. We are not selling any securities under
this prospectus and will not receive any of the proceeds from the sale of shares by the Selling Stockholders. However, we may receive
aggregate gross proceeds of up to approximately $1.2 million upon exercise of the Warrants for cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may sell or otherwise dispose of the Warrant Shares described in this prospectus in a number of different ways and
at varying prices. See the &ldquo;Plan of Distribution&rdquo; section of this prospectus for more information about how the Selling Stockholders
may sell or otherwise dispose of the Warrant Shares being registered pursuant to this prospectus. The Selling Stockholders may be deemed
&ldquo;underwriters&rdquo; within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders will pay all brokerage fees and commissions and similar expenses. We will pay the expenses (except brokerage fees
and commissions and similar expenses) incurred in registering the Warrant Shares, including legal and accounting fees. See &ldquo;Plan
of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on the NYSE American under the symbol &ldquo;AZTR.&rdquo; The last reported sale price of our Common Stock on
the NYSE American on July 22, 2025, was $0.23 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus, together with additional information described under the headings &ldquo;Where You Can Find Additional Information&rdquo;
and &ldquo;Incorporation of Certain Information by Reference&rdquo; carefully before you invest in any of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our Common Stock involves a high degree of risk. See &ldquo;Risk Factors&rdquo; on page 8 of this prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus is July 23,  2025.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PAGE</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDUSTRY AND MARKET DATA</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE FEBRUARY TRANSACTIONS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRADEMARKS, SERVICE MARKS AND TRADE NAMES</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">15</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#V_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">16</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">SELLING STOCKHOLDERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">24<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>25</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus or incorporated by reference herein. Neither we nor the Selling Stockholders
have authorized any other person to provide you with information different from or in addition to that contained in this prospectus,
and neither we nor the Selling Stockholders take responsibility for any other information others may give you. If anyone provides you
with different or inconsistent information, you should not rely on it. The Selling Stockholders are not making an offer to sell these
securities in any jurisdiction where an offer or sale is not permitted. Except as otherwise stated, you should assume that the information
appearing in this prospectus is accurate only as of the date on the front cover of this prospectus and that the information in any report
incorporated by reference is accurate only as of the date of such report. Our business, financial condition, results of operations and
prospects may have changed since such dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution
of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States
are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable
to that jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this prospectus, unless the context indicates or otherwise requires, the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
and &ldquo;our&rdquo; refer to Azitra, Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_001"></A>INDUSTRY
AND MARKET DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains or incorporates by reference observations, statistical data, estimates, and forecasts that are based on independent
industry, government and non-government organization publications or other publicly available information, as well as other information
based on our internal sources. Although we believe that the third-party sources referred to in this prospectus or incorporated by reference
are reliable, estimates as they relate to projections involve numerous assumptions, are subject to risks and uncertainties, and are subject
to change based on various factors, including those discussed under the section titled &ldquo;<I>Risk Factors</I>&rdquo; and elsewhere
in this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the
independent parties and by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information in the text of this prospectus or incorporated by reference is contained in independent industry government and non-governmental
organizational publications. The sources of these publications are provided below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stacy
    and Belkaid Study, <I>Apollo Stacy and Yasmine </I>Belkaid, Microbial Guardians of Skin Health. Science, 2019 Jan 18;363(6424):227-228.
    Doi: 10.1126/science.aat4326. PMID: 30655428</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oh
    Study, Zhou W, Spoto M, Hardy R, Guan C, Fleming E, Larson PJ, Brown JS, Oh J. Host-Specific Evolutionary and Transmission Dynamics
    Shape the Functional Diversification of Staphylococcus epidermidis in Human Skin. Cell. 2020 Feb 6;180(3):454-470.e18. doi: 10.1016/j.cell.2020.01.006.
    Epub 2020 Jan 30. PMID: 32004459; PMCID</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satoh
    Study, Satoh TK, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer HD, Rordorf T, Maul JT, Hafner J, Navarini AA, Contassot
    E, French LE. IL-36&gamma; drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest.
    2020 Mar 2;130(3):1417-1430. Doi: 10.1172/JCI128678. PMID: 31805013; PMCID: PMC7269569</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barbati
    Study, Netherton Syndrome in Children: Management and Future Perspectives, Federica Barbati, Mattia Giovannini Teresa Oranges, Lorenzo
    Lodi, Simona Barni, Elio Novembre, Ermanno Baldo, Mario Cristofolini, Stefano Stagi, Silvia Ricci, Francesca Mori, Cesare Filippeschi,
    Chiara Azzari and Giuseppe Indol; Frontiers in Pediatrics, May 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sun
    Study, Netherton syndrome: A case report and review of the literature, Joannie D. Sun, MD, and Kenneth G. Linden, PhD, MD, International
    Journal of Dermatology 2006</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orphanet,
    Netherton Syndrome, Orphanet: Netherton syndrome</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_002"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights certain information appearing elsewhere in this prospectus. Investing in our Common Stock involves a high degree of
risk. Because it is only a summary, it does not contain all of the information that you should consider before investing in our Common
Stock and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere
in this prospectus. Before you decide to invest in our Common Stock, you should read the entire prospectus carefully, including &ldquo;Risk
Factors&rdquo; beginning on page 8 and the financial statements and related notes included in this prospectus or incorporated by reference
herein.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered
proteins and topical live biotherapeutic products. We have built a proprietary platform that includes a microbial library comprised of
approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by
an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug-like
molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically
intractable strains. Our initial focus is on the development of genetically engineered strains of <I>Staphylococcus epidermidis, or S.
epidermidis</I>, which we consider to be an optimal therapeutic candidate species for engineering of dermatologic therapies. The particular
species demonstrates a number of well-described properties in the skin. As of the date of this prospectus, we have identified among our
microbial library over 60 distinct bacterial species that we believe are capable of being engineered to create living organisms or engineered
proteins with significant therapeutic effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pioneer in genetically engineered bacteria for therapeutic use in dermatology. Our goal is to leverage our platforms and internal
microbial library bacterial strains to create new therapeutics that are either engineered living organisms or engineered proteins or
peptides to treat skin diseases. Our initial focus is on the development of our current programs, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATR-12</B>,
    which includes a genetically modified strain of <I>S. epidermidis </I>for treating the orphan disease, Netherton syndrome, a chronic
    and sometimes fatal disease of the skin estimated to affect approximately one in every 100,000, but its prevalence may be underestimated
    due to misdiagnosis caused by similarities to other skin diseases. We received Pediatric Rare Disease Designation for ATR-12 by the
    United States Food and Drug Administration, or FDA, in 2020. In December 2022, we submitted an investigational new drug application,
    or IND, for a Phase 1b clinical trial in adult Netherton syndrome patients, and on January 27, 2023 we received notification from
    the FDA that the &ldquo;study may proceed&rdquo; with respect to the proposed Phase 1b clinical trial. After submitting post-IND
    manufacturing reports, we have commenced operating activities for our Phase 1b clinical trial in December 2023, and we dosed our
    first patient in August 2024. We reported initial safety results in the first half of 2025.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATR-04</B>,
    which includes a genetically modified strain of <I>S. epidermidis </I>for treating the papulopustular rash experienced by cancer
    patients undergoing epidermal growth factor receptor inhibitor, or EGFRi, targeted therapy. In August 2024, we obtained IND clearance
    from the FDA to commence a Phase 1/2 clinical trial in certain cancer patients undergoing EGFRi targeted therapy. In September 2024,
    we obtained Fast Track designation by the FDA in this indication. We expect to dose the first patient in the Phase 1/2 clinical trial
    in the third quarter of 2025.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ATR-01</B>,
    which includes a genetically modified strain of <I>S. epidermidis</I> that expresses an engineered recombinant human filaggrin protein
    for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), scaly skin disease with an estimated incidence and prevalence
    of 1 in 250, which suggests a total patient population of 1.3 million in the United States. We are planning to perform lead optimization
    and IND-enabling studies in 2025 to support an IND filing.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
    separate strains of bacterial microbes have been investigated and developed by us and Bayer Consumer Care AG, the consumer products
    division of Bayer AG, or Bayer, the international life science company. We entered into a Joint Development Agreement, or JDA, with
    Bayer in December 2019. Under the terms of the JDA, we are responsible for testing our library of bacterial strains and their natural
    products for key preclinical properties. After screening through hundreds of strains, we and Bayer have selected two particular strains
    to move forward into further development. Bayer holds the exclusive option to license the patent rights to these strains. As of the
    date of this prospectus, we have not negotiated a commercial license agreement with Bayer and we will not do so until such time,
    if ever, as Bayer exercises its option to acquire an exclusive royalty bearing license.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b3_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have established partnerships with teams from Carnegie Mellon University and the Fred Hutchinson Cancer Center, or Fred Hutch, two
of the premier academic centers in the United States. Our collaboration with the Carnegie Mellon based team also takes advantage of the
power of whole genome sequencing. This partnership is mining our proprietary library of bacterial strains for novel, drug like peptides
and proteins. The artificial intelligence/machine learning technology developed by this team predicts the molecules made by microbes
from their genetic sequences. The system then compares the predictions to the products actually made through tandem mass spectroscopy
and/or nuclear magnetic resonance imaging to refine future predictions. The predictions can be compared to publicly available 2D and
3D protein databases to select drug like structures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold an exclusive, worldwide license from Fred Hutch regarding the use of its patented SyngenicDNA Minicircle Plasmid, or SyMPL, technologies
for all fields of genetic engineering, including to discover, develop and commercialize engineered microbial therapies and microbial-derived
peptides and proteins for skin diseases. We are utilizing our licensed patent rights to build plasmids in order to make genetic transformations
that have never been previously achieved. To date, our team has successfully engineered our lead therapeutic candidates without the SyMPL
technology. However, we believe that SyMPL will open up the ability to make genetic transformations of an expanded universe of microbial
species, and we expect that some or all of our future product candidates will incorporate the SyMPL technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
our three lead product candidates and collaboration with Bayer, our goal is to develop a broad portfolio of product candidates focused
on expanding the application of our platforms for precision dermatology. We believe that we have established a unique position in advancing
the development of biologics for precision dermatology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to create a broad portfolio of product candidates for precision dermatology through our development of genetically engineered
proteins selected from our proprietary microbial library of approximately 1,500 unique bacterial strains. Our strategy is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Build
    a sustainable precision dermatology company</I></B>. Our goal is to build a leading precision dermatology company with a sustainable
    pipeline of product candidates. To that end, we are focused on rapidly advancing our current pipeline of live biotherapeutic candidates
    while actively developing additional product candidates. Each of our current product candidates are proprietary and subject to pending
    patent applications. We expect that most of our genetically engineered product candidates we develop will be eligible for patent
    protection.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advance
    our lead programs, ATR-12 and ATR-04, through clinical trials</I></B>. In 2022, we obtained pre-IND correspondence with the FDA for
    purposes of discussing our proposed regulatory pathway for the ATR-12 program and obtaining guidance from the FDA on the preclinical
    plan leading to the filing and acceptance of an IND for ATR-12. In December 2022, we filed an IND for an ATR-12 first-in-human trial
    in Netherton syndrome patients. On January 27, 2023, we received notification from the FDA that the &ldquo;study may proceed&rdquo;
    with respect to the proposed Phase 1b clinical trial, and in August 2024 we initiated dosing the first patient in the ATR-12 Phase
    1b clinical trial. In August 2024, we received IND clearance from the FDA for a first-in-human Phase 1b/2a clinical trial in patients
    with EGFRi-associated rash, and in September 2024, the FDA granted Fast Track designation for the ATR-04 program. We commenced a
    Phase 1b trial for our ATR-04 program in certain cancer patients undergoing EGFRi therapy in the fourth quarter of 2024. We expect
    to dose the first patient in the ATR-04 Phase 1/2 clinical trial in the third quarter of 2025. We reported initial safety results
    of the first patients dosed in our ATR-12 Phase 1b clinical trial in Netherton syndrome patients in the first half of 2025.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Broaden
    our platform by selectively exploring strategic partnerships that maximize the potential of our precision dermatology programs</I></B>.
    We intend to maintain significant rights to all of our core technologies and product candidates. However, we will continue to evaluate
    partnering opportunities in which a strategic partner could help us to accelerate development of our technologies and product candidates,
    provide access to synergistic combinations, or provide expertise that could allow us to expand into the treatment of different types
    of skin diseases. We may also broaden the reach of our platform by selectively in-licensing technologies or product candidates. In
    addition, we will consider potentially out-licensing certain of our proprietary technologies for indications and industries that
    we are not pursuing. We believe our genetic engineering techniques and technologies have applicability outside of the field of medicine,
    including cosmetics and in the generation of clean fuels and bioremediation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leverage
    our academic partnerships</I></B>. We currently have partnerships with investigators at the Fred Hutchinson Cancer Center, Yale University,
    Duke University, and Carnegie Mellon University. We expect to leverage these partnerships and potentially expand them or form other
    academic partnerships to bolster our engineering platforms and expand our research and development pipeline.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expand
    on our other potential product candidates</I></B>. Beyond our three lead product candidates, our goal is to develop a broad portfolio
    of product candidates focused on expanding the application of our platforms for precision dermatology. We have a proprietary platform
    for discovering and developing therapeutic products for precision dermatology. Our platform is built around a microbial library comprised
    of approximately 1,500 unique bacterial strains to allow screening for unique therapeutic characteristics and utilizes a microbial
    genetic technology that analyzes, predicts and engineers the proteins, peptides and molecules made by skin microbes. Our ability
    to genetically engineer intractable microbial species is uniquely leveraged by our exclusive license to the SyMPL technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we own three issued U.S. patents, twelve pending U.S. patent applications, three pending PCT applications
and 58 other foreign patents and patent applications that are important to the development of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Leadership Team</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are led by Francisco D. Salva, our chief executive officer, and Travis Whitfill Ph.D. MPH, our co-founder and chief operating officer,
who have more than 35 years of combined experience in the management of biotechnology companies and healthcare investing. Mr. Salva was
previously a co-founder of Acerta Pharma, which was sold to AstraZeneca for approximately $6.3 billion in a staged acquisition in 2016.
He also worked on the turnaround of Pharmacyclics, which subsequently sold to Abbvie for approximately $21 billion in 2015. Before that,
Mr. Salva spent almost a decade in life sciences venture capital. Dr. Whitfill served as associate research scientist and serves as assistant
professor adjunct at Yale University with appointments in the Departments of Pediatrics and Emergency Medicine. He spent nearly a decade
in venture capital as a partner in a biotech-focused venture capital fund, Bios Partners. He has led numerous grant-funded projects,
holds nearly a dozen patents and has co-authored over 60 publications. Our board of directors (the &ldquo;Board&rdquo;) is comprised
of renowned group of senior executives, scientists and investors in the biotechnology industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Competitive Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a pioneer in genetically engineering bacteria for therapeutic use in dermatology clinical trials. We have built a proprietary platform
that includes a microbial library comprised of approximately 1,500 unique bacterial strains that are screened for therapeutic characteristics
as well as lead drug candidates. Furthermore, we have exclusively licensed a novel technology, which potentially enables the genetic
transformation of previously intractable bacterial microbes. The history of recombinant protein engineering in biotech has traditionally
been limited to less than 20 species. Our licensed technology opens up the potential to genetically engineer thousands of microbial species
to build proteins and peptides that have never been previously built. Our management team has significant experience in discovering,
developing, manufacturing and commercializing therapeutics. The members of our leadership team have specialized expertise developed at
companies including Pharmacyclics, Acerta Pharma, Castle Creek Biosciences, VYNE Therapeutics (fka Menlo Therapeutics), Revance Therapeutics,
Biogen, Novartis and Connetics Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Market Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there are significant market opportunities to capture in each of our addressable markets. The dermatology market itself has shown
considerable growth over the last decade and is predicted to continue to grow. According to Vision Research Reports, the dermatology
drug market surpassed $17 billion in 2021 and is expected to grow at a compound annual growth rate of 8.8% through 2030. Our first product
candidate to emerge from our platform focuses on the orphan indication of Netherton syndrome. Based on the Barbati and Sun Studies, we
believe that this product candidate represents a potential $250 million global sales opportunity by mid-2030. Our second product candidate
focuses on papulopustular rash due to EGFR inhibitors. We believe this product candidate represents a potential $1 billion global sales
opportunity by 2030. The diseases we intend to target are well characterized, often by a monogenic genetic mutation. Additionally, the
era of genomic sequencing has ushered in unprecedented progress in genetic testing. The defined molecular pathophysiology of over 100
rare skin diseases has now been defined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Corporate Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated under the laws of the state of Delaware on January 2, 2014. Our principal executive offices are located at 21 Business
Park Drive, Branford, Connecticut 06405, and our telephone number is (203) 646-6446. Our website address is www.azitrainc.com. The information
contained in, or accessible through, our website is not incorporated by reference into this prospectus, and you should not consider any
information contained in, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase
our Common Stock or Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own U.S. and foreign registered trademarks, including our company name. All other trademarks or trade names referred to in this prospectus
are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to
without the symbols &reg; and &trade;, but such references should not be construed as any indication that their respective owners will
not assert, to the fullest extent under applicable law, their rights thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information related to our business and operations, please refer to the reports incorporated herein by reference, as described
in the section entitled &ldquo;<I>Incorporation of Certain Documents by Reference</I>&rdquo; in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Jumpstart Our Business Startups Act, or the JOBS Act, was enacted in April 2012 with the intention of encouraging capital formation in
the United States and reducing the regulatory burden on newly public companies that qualify as &ldquo;emerging growth companies.&rdquo;
We are an emerging growth company within the meaning of the JOBS Act. As an emerging growth company, we may take advantage of certain
exemptions from various public reporting requirements, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement that our internal control over financial reporting be attested to by our independent registered public accounting firm
    pursuant to Section 404 of the Sarbanes-Oxley Act of 2002;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    requirements related to the disclosure of executive compensation in this prospectus and in our periodic reports and proxy statements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to delay compliance with new or revised financial accounting standards until private companies are required to comply with
    the new or revised financial accounting standard.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of the exemptions under the JOBS Act discussed above until we are no longer an emerging growth company. We will remain
an emerging growth company until the earliest to occur of (1) the last day of the fiscal year in which we have $1.235 billion or more
in annual revenue; (2) the date we qualify as a &ldquo;large accelerated filer,&rdquo; with at least $700 million of equity securities
held by non-affiliates; (3) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt
securities; or (4) the last day of the fiscal year ending after the fifth anniversary of the IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to take advantage of some, but not all, of the available benefits under the JOBS Act. We have chosen to take advantage of
all of the other exemptions discussed above. Accordingly, the information contained herein and in our subsequent filing with the SEC
may be different than the information you receive from other public companies in which you hold stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Smaller Reporting Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are a &ldquo;smaller reporting company&rdquo; as defined in Rule 10(f)(1) of Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements.
We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our Common Stock held
by non-affiliates equals or exceeds $250 million as of the end of that year&rsquo;s second fiscal quarter, or (2) our annual revenues
equaled or exceeded $100 million during such completed fiscal year and the market value of our Common Stock held by non-affiliates equals
or exceeds $700 million as of the end of that year&rsquo;s second fiscal quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>February
Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&ldquo;The February Transactions&rdquo; for a description of the February transactions and the Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_003"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 1.5in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.1in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock offered by the Selling Stockholders</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to 2,245,968 Warrant Shares that we may issue pursuant to any exercise of the Warrants.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
    Price</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Selling Stockholders will sell the shares at prevailing market prices or privately negotiated prices.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock outstanding immediately before this offering</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,676,354
    shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock to be outstanding after this offering</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,922,322
    shares of Common Stock, assuming that all Warrants that we issue pursuant to the Letter Agreement are exercised.<SUP>(1)</SUP></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of proceeds</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Selling Stockholders will receive all of the proceeds from the sale of the Warrant Shares offered for sale by it under this prospectus.
    We will not receive proceeds from the sale of the Warrant Shares by the Selling Stockholders. However, we may receive aggregate gross
    proceeds of up to approximately $1.2 million if the Warrants are exercised for cash. Any proceeds from the Selling Stockholders that
    we receive under the exercise of the Warrants are expected to be used for working capital and other general corporate purposes. See
    &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    market and symbol</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Common Stock is listed on the NYSE American under the symbol &ldquo;AZTR.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    factors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our securities involves a high degree of risk. See the section titled &ldquo;<I>Risk Factors</I>&rdquo; and the other information
    in this prospectus for a discussion of the factors you should consider carefully before you decide to invest in our securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The number of shares of our Common Stock to be outstanding after this offering is based on approximately 20,676,354 shares of our Common
Stock outstanding as of July 22, 2025, and excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,608
    shares of our Common Stock issuable upon exercise of outstanding options, with a weighted average exercise price of $41.60 per share,
    granted pursuant to our 2016 Stock Incentive Plan (the &ldquo;2016 Plan&rdquo;) and our 2023 Stock Incentive Plan (the &ldquo;2023
    Plan&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
    16,638,593 shares of our Common Stock issuable upon exercise of outstanding warrants, with a weighted average exercise price
    of $0.79 per share; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,457
    shares of our Common Stock reserved for future grants under our 2016 Plan and 1,209,734 shares of our Common Stock reserved for future
    grants under our 2023 Plan</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
we indicate otherwise or unless the context otherwise requires, all information in this prospectus assumes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of outstanding warrants or options described above; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the Warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Any
investment in our securities involves a high degree of risk. You should carefully consider the risks described below and set forth in
the section &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended 2024 (the &ldquo;2024 Form 10-K&rdquo;),
as well as any amendment or update to our risk factors reflected in subsequent filings with the SEC, which are incorporated by reference
in this prospectus, and all other information contained in this prospectus and incorporated by reference in this prospectus, before you
make a decision to invest in our securities. Please note that the risks highlighted here are not the only ones that we may face. For
example, additional risks presently unknown to us or that we currently consider immaterial or unlikely to occur could also impair our
operations. If any of the following events occur or any additional risks presently unknown to us actually occur, our business, financial
condition and operating results may be materially adversely affected. In that event, the trading price of our Common Stock could decline
and you could lose all or part of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
an investor, you may lose all of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in our securities involves a high degree of risk. As an investor, you may never recoup all, or even part, of your investment and you
may never realize any return on your investment. You must be prepared to lose all of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need additional financing to execute our business plan and fund operations, which additional financing may not be available on reasonable
terms or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2025, we had total assets of $5,907,891 and working capital of approximately $2.6 million. We believe that our cash on hand
as of the date of this prospectus will not be sufficient to cover our proposed plan of operations over, at least, the next 12 months.
We intend to seek additional funds through various financing sources, including the sale of our equity, licensing fees for our technology
and joint ventures with industry partners. In addition, we will consider alternatives to our current business plan that may enable to
us to achieve revenue producing operations and meaningful commercial success with a smaller amount of capital. However, there can be
no guarantees that such funds will be available on commercially reasonable terms, if at all. If such financing is not available on satisfactory
terms, we may be unable to further pursue our business plan and we may be unable to continue operations, in which case you may lose your
entire investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of our independent registered public accounting firm for the year ended December 31, 2024 states that due to our accumulated deficit,
recurring and negative cash flow from operations there is substantial doubt about our ability to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our Common Stock may be subject to fluctuation and volatility. You could lose all or part of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our Common Stock is subject to wide fluctuations in response to various factors, some of which are beyond our control.
Since shares of our Common Stock were sold in our initial public offering (&ldquo;IPO&rdquo;) in June 2023 at a price of $150.00 per
share, the reported high and low sales prices of our Common Stock have ranged from $155.40 to $0.2275 through July 17,
2025. The market price of our Common Stock on the NYSE American may fluctuate as a result of a number of factors, some of which are beyond
our control, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in our and our competitors&rsquo; results of operations and financial condition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in earnings estimates or recommendations by securities analysts, if our shares are covered by analysts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    acceptance of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
    of technological innovations or new competitive products by others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of technological innovations or new products by us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
    of the results of preclinical or clinical trials for our product candidates;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us to achieve a publicly announced milestone;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    between our expenditures to develop and market new or enhanced products and the generation of sales from those products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    concerning intellectual property rights, including our involvement in litigation brought by or against us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the amounts that we spend to develop, acquire or license new products, technologies or businesses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in our expenditures to promote our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    sale or proposed sale, or the sale by our significant stockholders, of our shares or other securities in the future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in key personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    or failure of our research and development projects or those of our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    trading volume of our shares; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic and market conditions and other factors, including factors unrelated to our operating performance.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
factors and any corresponding price fluctuations may materially and adversely affect the market price of our shares and result in substantial
losses being incurred by our investors. In the past, following periods of market volatility, public company stockholders have often instituted
securities class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and divert
the resources and attention of our management from our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
charter limits our ability to issue shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
charter authorizes us to issue up to 200,000,000 shares of Common Stock. With 20,676,354 shares of Common Stock issued and outstanding
as of the date of this prospectus, 41,608 options, and 16,698,593 warrants outstanding, as well as 7,457 shares reserved for issue under
our 2016 equity plan and 1,209,734 shares reserved under our 2023 equity incentive plan, 179,323,646 shares of Common Stock remain issuable
as of the date of this prospectus. The number of shares issued and outstanding may increase depending upon any additional issuances of
shares and shares underlying warrants pursuant to the purchase agreement with Alumni Capital LP. Additional shares may become issuable
with the expiration of currently outstanding warrants or if we effect a reverse share split in the future. We may register additional
shares as they become issuable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
issuance of Common Stock to the Selling Stockholders may cause substantial dilution to our existing stockholders, and the sale of such
shares acquired by the Selling Stockholders could cause the price of our Common Stock to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering for resale by the Selling Stockholders up to 2,245,968 Warrant Shares issuable upon exercise of the Warrants. The number
of shares of our Common Stock ultimately offered for resale by the Selling Stockholders under this prospectus is dependent upon the number
of Warrant Shares issued upon exercise of the Warrants by the Selling Stockholder. Depending on a variety of factors, including market
liquidity of our Common Stock, the issuance of Warrant Shares to the Selling Stockholders may cause the trading price of our Common Stock
to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may sell all, some or none of such Warrant Shares. The sale of a substantial number of Warrant Shares by the Selling
Stockholders in this offering, or anticipation of such sales, could cause the trading price of our Common Stock to decline or make it
more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise desire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investors
who buy shares at different times will likely pay different prices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
who purchase shares in this offering at different times will likely pay different prices, and so may experience different levels of dilution
and different outcomes in their investment results. The Selling Stockholders may sell the Warrant Shares at different times and at different
prices. Investors may experience a decline in the value of the shares they purchase from the Selling Stockholders in this offering as
a result of sales made by us in future transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
failure to meet the continued listing requirements of the NYSE American could result in a delisting of our Common Stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to satisfy the continued listing requirements of the NYSE American, such as the corporate governance requirements or the minimum
closing bid price requirement, the NYSE American may take steps to delist our Common Stock. Such a delisting would likely have a negative
effect on the price of our Common Stock and would impair your ability to sell or purchase our Common Stock when you wish to do so. In
the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would
allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our Common Stock, prevent our Common
Stock from dropping below the NYSE American&rsquo;s minimum bid price requirement or prevent future non-compliance with the NYSE American&rsquo;s
listing requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
capital raises may dilute your ownership and/or have other adverse effects on our operations</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional capital by issuing equity securities, our existing stockholders&rsquo; percentage ownership will be reduced and these
stockholders may experience substantial dilution. If we raise additional funds by issuing debt securities, these debt securities would
have rights senior to those of our Common Stock and the terms of the debt securities issued could impose significant restrictions on
our operations, including liens on our assets. If we raise additional funds through collaborations and licensing arrangements, we may
be required to relinquish some rights to our intellectual property or candidate products, or to grant licenses on terms that are not
favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have not paid dividends on our Common Stock in the past and have no immediate plans to pay such dividends</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to reinvest all of our earnings, to the extent we have earnings, to cover operating costs and otherwise become and remain competitive.
We do not plan to pay any cash dividends with respect to our Common Stock in the foreseeable future. We cannot assure you that we would,
at any time, generate sufficient surplus cash that would be available for distribution to the holders of our Common Stock as a dividend.
Therefore, you should not expect to receive cash dividends on the Common Stock we are offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_005"></A>The
FEBRUARY TransactionS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2025, we entered into a placement agency agreement (the &ldquo;Placement Agency Agreement&rdquo;) with Maxim Group LLC (the
&ldquo;Placement Agent&rdquo;) in connection with the offer and sale to investors (the &ldquo;Investors&rdquo;) of 2,495,518 shares of
the Company&rsquo;s Common Stock, at an offering price of $0.2785 per share (the &ldquo;February RDO &ldquo;) pursuant to a securities
purchase agreement dated February 4, 2025 (the &ldquo;Initial Purchase Agreement&rdquo;). The Initial Purchase Agreement was amended
and restated on February 5, 2025 (the &ldquo;A&amp;R Purchase Agreement&rdquo;). The shares of Common Stock were offered by the Company
pursuant to a shelf registration statement on Form S-3 (File No. 333-280648), which was declared effective by the SEC on July 8, 2024,
the base prospectus included therein, and a prospectus supplement dated February 4, 2025. The aggregate gross proceeds to the Company
from the February RDO were approximately $693,803, before deducting placement agent fees and other estimated offering expenses. The February
RDO closed on February 6, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2025, in connection with the Investors&rsquo; agreement to amend the Initial Purchase Agreement and enter into the A&amp;R
Purchase Agreement, the Company and the Investors entered into the Letter Agreement, pursuant to which the Company (i) issued the Investors
the Warrants to purchase up to 2,245,968 shares of Common Stock, in the aggregate and (ii) granted the Investors a right for two years
from the closing date of the Letter Agreement, to participate in future financings of the Company in an aggregate amount equal to 50%
of such financings (the &ldquo;Letter Agreement Offering&rdquo;). Pursuant to the terms of the Letter Agreement, the Company must file
a registration statement with the SEC covering the issuance of the Warrant Shares underlying the Warrants and use its best efforts to
cause the registration statement to become effective by the six-month anniversary of the closing of the Letter Agreement. The filing
of the registration statement of which this prospectus forms a part was made to satisfy this obligation. The Warrants are exercisable
on the six-month and one day anniversary of their issuance, and their exercise price is equal to $0.54, subject to adjustment in accordance
with the terms of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_006"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains or incorporates by reference forward-looking statements. The words &ldquo;believe,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;potentially,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo;
&ldquo;would,&rdquo; &ldquo;project,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect&rdquo; and similar expressions that convey uncertainty
of future events or outcomes are intended to identify forward-looking statements. These forward-looking statements include, but are not
limited to, statements concerning the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    future financial and operating results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    intentions, expectations and beliefs regarding anticipated growth, market penetration and trends in our business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing and success of our plan of commercialization;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to successfully develop and clinically test our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain FDA approval for any of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to comply with all U.S. and foreign regulations concerning the development, manufacture and sale of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third parties to manufacture our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    adequacy of the net proceeds of this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effects of market conditions on our stock price and operating results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain, protect and enhance our intellectual property;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effects of increased competition in our market and our ability to compete effectively;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    plans to use the proceeds from this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    associated with initiating and defending intellectual property infringement and other claims;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    attraction and retention of qualified employees and key personnel;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    acquisitions of or investments in complementary companies or technologies; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to comply with evolving legal standards and regulations, particularly concerning requirements for being a public company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the &ldquo;<I>Risk
Factors</I>&rdquo; section of our 2024 Form 10-K and elsewhere in this prospectus. Moreover, we operate in a very competitive and rapidly
changing environment, and new risks emerge from time to time. It is not possible for us to predict all risks, nor can we assess the impact
of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially
from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking
events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those
anticipated or implied in our forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes
responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any
forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes
in our expectations, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus, the documents incorporated by reference in this prospectus, the documents that we reference in this prospectus
and have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that
our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_007"></A>TRADEMARKS,
SERVICE MARKS AND TRADE NAMES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to use a number of registered and common law trademarks, service marks and/or trade names in connection with our business
in the United States and/or in certain foreign jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are without the &reg; and &trade;
symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains
additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service
marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our
use or display of other companies&rsquo; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement
or sponsorship of us by, any other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt -20pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_008"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to shares of Common Stock that may be offered and sold from time to time by the Selling Stockholders. We will not
receive any proceeds from the resale of shares of Common Stock by the Selling Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt -40pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may receive up to approximately $1.2 million if the Warrants are exercised for cash. See the &ldquo;Plan of Distribution&rdquo; section
of this prospectus for more information. Any proceeds from the Selling Stockholders that we receive upon exercise of the Warrants for
cash are currently expected to be used primarily for working capital and general corporate purposes. Pending these uses, we expect to
invest the net proceeds in short-term, interest-bearing securities. We cannot predict when, or if, the Warrants will be exercised for
cash. Further, in certain circumstances, the Selling Stockholders may exercise the Warrants on a cashless basis. As a result, we cannot
specify with certainty all of the particular uses for the net proceeds that we will have. Management will retain broad discretion over
the allocation of any net proceeds it receives as a result of the exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will incur all costs associated with this prospectus and the registration statement of which it is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_009"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our Common Stock and we do not anticipate paying any cash dividends on our Common Stock
in the foreseeable future. Investors should not purchase our Common Stock with the expectation of receiving cash dividends. The payment
of dividends on our Common Stock, if any, in the future is within the discretion of our Board and will depend on our earnings, capital
requirements and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to finance
the development and growth of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="V_010"></A>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description summarizes the most important terms of our capital stock. Because it is only a summary, it does not contain all
the information that may be important to you. For a complete description of the matters set forth in this &ldquo;Description of Securities,&rdquo;
you should refer to our amended and restated certificate of incorporation and amended and restated bylaws and investor rights agreement,
which are included as exhibits to the registration statement of which this prospectus forms a part, and to the applicable provisions
of Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 200,000,000 shares of Common Stock, $0.0001 par value per share, and 10,000,000 shares of undesignated
preferred stock, $0.0001 par value per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are 20,676,354 shares of our Common Stock outstanding and no shares of our preferred stock outstanding as of the date of this prospectus.
As of the date of this prospectus, we had 34 stockholders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Common Stock are entitled to one vote for each share of Common Stock. The holders of Common Stock are entitled to any dividends
that may be declared by the Board out of funds legally available for payment of dividends at such times and in such amounts as the Board
in its discretion. In the event of any liquidation, dissolution or winding up of the Company, holders of Common Stock are entitled to
receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares of Common
Stock held by the holders of Common Stock. The holders of shares of Common Stock have no preemptive, conversion, subscription rights
or cumulative voting rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, there are a total of 10,000,000 shares of undesignated preferred stock authorized for issuance, none
of which are outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board is authorized, without further action by our stockholders, to provide from time to time out of the unissued shares of preferred
stock for one or more series of preferred stock, and with respect to each such series, to fix the number of shares constituting such
series and the designation of such series, the powers (including voting powers), if any, of the shares of such series and the preferences
and relative, participating, optional, special or other rights, if any, and the qualifications, limitations, or restrictions, if any,
of the shares of such series. The issuance of our preferred stock could adversely affect the voting power of holders of our Common Stock
and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred
stock could have the effect of delaying, deferring, or preventing a change of control or other corporate action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have outstanding the following warrants to purchase shares of our Common Stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued in connection with our April 2018 placement of unsecured convertible promissory notes to purchase up to an aggregate of 1,596
    shares of our Common Stock, at a per share exercise price equal to $14.40. The warrants expire in April 2028.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued in connection with our February 2019 placement of Series A-1 convertible preferred shares to purchase up to an aggregate of
    7,195 shares of our Common Stock, at a per share exercise price equal to $158.40. The warrants expire in February 2026.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued to the underwriter of our IPO to purchase 2,000 shares of our Common Stock. These warrants are exercisable at $187.50 per
    share. The warrants expire in June 2028.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued to the underwriter of our February 2024 public offering to purchase 22,223 shares of our Common Stock. These warrants are
    exercisable at $11.25 per share. The warrants expire in February 2029.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued in connection with our July 2024 follow-on public offering to purchase 13,329,000 shares of our Common Stock. These warrants
    are exercisable at $0.7043 per share. The warrants expire in July 2029</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued to the underwriter of our July 2024 follow-on offering to purchase 266,600 shares of our Common Stock. These warrants are
    exercisable at $1.88 per share. The warrants expire in July 2029.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued to the underwriter of our January 2025 public offering to purchase 194,311 shares of our Common Stock. These warrants are
    exercisable at $0.38 per share. The warrants expire in January 2030.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued in connection with our February 2025 follow-on offering to purchase 2,245,968 shares of our Common Stock. These warrants are
    exercisable at $0.54 per share. The warrants expire in August 2030. The shares underlying these Warrants are being registered hereunder.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    issued in connection with our equity line of credit to purchase in aggregate 569,700 shares of our Common Stock. These warrants
    are exercisable at ranges from $0.26 to $0.35 per share depending on their respective date of issuance. The warrants have
    expiration dates ranging from May 2025 to July 2025.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
Incentive Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted the Azitra, Inc. 2016 Stock Incentive Plan (the &ldquo;2016 Plan&rdquo;) providing for the grant of non-qualified stock
options and incentive stock options to purchase shares of our Common Stock and for the grant of restricted and unrestricted share grants
and restricted stock units. We currently have reserved 7,457 shares of our Common Stock under the 2016 Plan. The purpose of the 2016
Plan is to provide eligible participants with an opportunity to acquire an ownership interest in our company. All officers, directors,
employees and consultants to our company are eligible to participate under the 2016 Plan. The 2016 Plan provides that options may not
be granted at an exercise price less than the fair market value of our shares of Common Stock on the date of grant. As of the date of
this prospectus, we have outstanding options granted under the 2016 Plan to purchase an aggregate of 40,276 shares of our Common Stock
at an average exercise price of $40.92 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, our Board and stockholders approved and adopted the Azitra, Inc. 2023 Stock Incentive Plan (the &ldquo;2023 Plan&rdquo;)
providing for the grant of non-qualified stock options and incentive stock options to purchase shares of our Common Stock and for the
grant of restricted and unrestricted share grants and restricted stock units. In November 2024, our stockholders approved amendments
to the 2023 Plan that (i) increased the number of shares of Common Stock that may be issued under the 2023 Plan by 1,144,401 shares and
(ii) adopted an evergreen provision to the 2023 Plan providing for an automatic 5% annual increase in the shares of Common Stock available
for issuance under the 2023 Plan over the next 10 years, commencing on January 1, 2026. We currently have reserved 1,211,068 shares of
our Common Stock under the 2023 Plan. The purpose of the 2023 Plan is to provide eligible participants with an opportunity to acquire
an ownership interest in our company. All officers, directors, employees and consultants to our company are eligible to participate under
the 2023 Plan. The 2023 Plan provides that options may not be granted at an exercise price less than the fair market value of our shares
of Common Stock on the date of grant. As of the date of this report, we have outstanding options granted under the 2023 Plan to purchase
an aggregate of 1,333 shares of our Common Stock at an average exercise price of $62.10 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate the payment of cash dividends on our Common Stock in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
holders of our Common Stock, or their permitted transferees, are entitled to the registration rights described below. The registration
of shares of our Common Stock pursuant to the exercise of registration rights described below would enable the holders to sell these
shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the
registration expenses, other than the underwriting discounts and commissions, of the shares registered pursuant to the registrations
described below. The registration rights described below will expire upon the earlier of June 20, 2026 or when all investors, considered
with their affiliates, can sell all of their shares in a three-month period under Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Convertible
Preferred Stock Registration Rights</I>. In connection with our convertible preferred stock financings, we entered into an investor rights
agreement, as amended, pursuant to which we have granted the purchasers of our convertible preferred stock certain demand and piggyback
registration rights. Those parties beneficially hold approximately 217,082 shares of our Common Stock, including 5,612 shares of our
Common Stock issuable upon exercise of warrants issued to the parties in connection with our 2018 placement of our unsecured convertible
promissory notes and our 2019 placement of Series A-1 convertible preferred shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the investor rights agreement, we are required, upon the written request by the holders of at least 50% of the shares that are entitled
to registration rights under the investor rights agreement, to register, as soon as practicable, all or a portion of these shares for
public resale. We are required to effect two demand registrations pursuant to a registration statement on Form S-1. Subject to our eligibility
to use a registration statement on Form S-3, we are required to effect an unlimited number of demand registrations pursuant to Form S-3,
provided such requests for registration be for an aggregate offering price, net of the underwriting discounts and commissions, equal
or greater than $1 million. Pursuant to the investor rights agreement, we have also granted to the piggyback registration rights and
demand registration rights. These demand and piggyback registration rights terminate as to each investor when their shares subject to
the registration rights agreement may be sold by the investor pursuant to Rule 144 under the Securities Act without regard to both the
volume limitations for sales as provided in Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2024, we filed with the SEC a registration statement on Form S-3 to register the resale of the 217,082 shares of Common Stock
held by the stockholders holding demand registration rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Underwriter
Registration Rights. </I>In connection with our IPO and February 2024 public offering, we issued to the representative of the underwriters
or its designees warrants, referred to as the Representative&rsquo;s Warrants, to purchase up to a total of 2,000 shares and 22,222 shares
of our Common Stock, respectively. The Representative&rsquo;s Warrants provide for registration rights (including a one-time demand registration
right and unlimited piggyback rights) consistent with FINRA Rule 5110.05. The demand for registration may be made at any time beginning
on the initial exercise date of the Representative&rsquo;s Warrants and expiring on the fifth anniversary of the date of the public offering
prospectus to which the warrants relate in accordance with FINRA Rule 5110(g)(8)(C). In addition to the one-time demand registration
right, the Representative&rsquo;s Warrants have unlimited piggyback rights, for a period of no more than two years from the initial exercise
date of the Representative&rsquo;s Warrants in accordance with FINRA Rule 5110(g)(8)(D).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>January
2025 Offering</I>. In connection with the offering of securities pursuant to our shelf registration statement on Form S-3 that we completed
in January 2025, we issued to the placement agent or its designees warrants, referred to as the January Placement Agent Warrants, to
purchase up to a total of 194,311 shares of our Common Stock. The January Placement Agent Warrants provide for registration rights (including
a one-time demand registration right and unlimited piggyback rights) consistent with FINRA Rule 5110.05. The demand for registration
may be made at any time beginning on the initial exercise date of the January Placement Agent Warrants and expiring on the fifth anniversary
of the date of the public offering prospectus to which the warrants relate in accordance with FINRA Rule 5110(g)(8)(C).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Alumni
Capital LP Equity Line of Credit</I>. The Company entered into a purchase agreement (the &ldquo;ELOC Purchase Agreement&rdquo;) with
Alumni Capital LP (&ldquo;Alumni&rdquo;) in April 2025 through which the Company has the right, but not the obligation, to sell to Alumni,
and Alumni is obligated to purchase, up to an aggregate of $20 million (the &ldquo;Investment Amount&rdquo;) of shares (the &ldquo;ELOC
Shares&rdquo;) of the Company&rsquo;s Common Stock in a series of purchases. Upon each purchase, Alumni receives warrants to purchase
such number of shares of the Company&rsquo;s Common Stock equal to 10% of the number of ELOC Shares purchased in the related purchase
(the &ldquo;ELOC Warrants&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2025, we filed with the SEC a registration statement on Form S-1 (File No. 333-286809) to register the resale of 73,578,595
shares of Common Stock, which represents (i) 66,889,632 ELOC Shares that we may issue and sell to Alumni under the ELOC Purchase Agreement
and (ii) 6,688,963 shares of Common Stock underlying the ELOC Warrants that are issuable upon exercise of the ELOC Warrants that we may
issue to Alumni in connection with any single fixed purchase under the ELOC Purchase Agreement. The Form S-1 was declared effective on
May 1, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
on the market prices of the Company&rsquo;s Common Stock at the time it elects to issue and sell ELOC Shares and ELOC Warrants to Alumni
under the ELOC Purchase Agreement, we may need to register for resale under the Securities Act additional shares of our Common Stock
in order to receive aggregate gross proceeds equal to the full Investment Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anti-Takeover
Effects of Certain Provisions of Delaware Law and Our Charter Documents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of certain provisions of Delaware law and our amended and restated certificate of incorporation and amended and
restated bylaws. This summary does not purport to be complete and is qualified in its entirety by reference to the corporate law of Delaware
and our amended and restated certificate of incorporation and amended and restated bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to Section 203 of the Delaware General Corporation Law, an anti-takeover law. In general, Section 203 prohibits a Delaware
corporation from engaging in any business combination (as defined below) with any interested stockholder (as defined below) for a period
of three years following the date that the stockholder became an interested stockholder, unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior
                                            to that date, the board of directors of the corporation approved either the business combination
                                            or the transaction that resulted in the stockholder becoming an interested stockholder;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon
                                            consummation of the transaction that resulted in the stockholder becoming an interested stockholder,
                                            the interested stockholder owned at least 85% of the voting stock of the corporation outstanding
                                            at the time the transaction commenced, excluding for purposes of determining the number of
                                            shares of voting stock outstanding (but not the voting stock owned by the interested stockholder)
                                            those shares owned by persons who are directors and officers and by excluding employee stock
                                            plans in which employee participants do not have the right to determine whether shares held
                                            subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            or subsequent to that date, the business combination is approved by the board of directors
                                            of the corporation and authorized at an annual or special meeting of stockholders, and not
                                            by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting
                                            stock that is not owned by the interested stockholder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 defines &ldquo;business combination&rdquo; to include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            merger or consolidation involving the corporation and the interested stockholder;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation
                                            involving the interested stockholder;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to certain exceptions, any transaction that results in the issuance or transfer by the corporation
                                            of any stock of the corporation to the interested stockholder;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to limited exceptions, any transaction involving the corporation that has the effect of increasing
                                            the proportionate share of the stock of any class or series of the corporation beneficially
                                            owned by the interested stockholder; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.25in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            receipt by the interested stockholder of the benefit of any loans, advances, guarantees,
                                            pledges or other financial benefits provided by or through the corporation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting
stock of the corporation, or who beneficially owns 15% or more of the outstanding voting stock of the corporation at any time within
a three-year period immediately prior to the date of determining whether such person is an interested stockholder, and any entity or
person affiliated with or controlling or controlled by any of these entities or persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Charter Documents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
charter documents include provisions that could have the effect of discouraging others from making tender offers for our shares and may
have the effect of deterring hostile takeovers or delaying changes in our control or management. These provisions are intended to enhance
the likelihood of continued stability in the composition of our Board and its policies and to discourage certain types of transactions
that may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited
acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions may have the effect
of discouraging, delaying or preventing a change in control or an unsolicited acquisition proposal that a stockholder might consider
favorable, including a proposal that might result in the payment of a premium over the market price for the shares held by our stockholders.
Certain of these provisions are summarized in the following paragraphs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effects
of authorized but unissued Common Stock and preferred stock</I>. One of the effects of the existence of authorized but unissued Common
Stock and preferred stock may be to enable our Board to make more difficult or to discourage an attempt to obtain control of our Company
by means of a merger, tender offer, proxy contest or otherwise, and thereby to protect the continuity of management. If, in the due exercise
of its fiduciary obligations, the Board were to determine that a takeover proposal was not in our best interest, such shares could be
issued by the Board without stockholder approval in one or more transactions that might prevent or render more difficult or costly the
completion of the takeover transaction by diluting the voting or other rights of the proposed acquirer or insurgent stockholder group,
by putting a substantial voting block in institutional or other hands that might undertake to support the position of the incumbent Board,
by effecting an acquisition that might complicate or preclude the takeover, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cumulative
Voting</I>. Our amended and restated certificate of incorporation does not provide for cumulative voting in the election of directors,
which would allow holders of less than a majority of the stock to elect some directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Vacancies</I>.
Our amended and restated bylaws provide that all vacancies may be filled by the affirmative vote of a majority of directors then in office,
even if less than a quorum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special
Meeting of Stockholders and Stockholder Action by Written Consent</I>. A special meeting of stockholders may only be called by our Board
or the chairperson of our Board. All stockholder actions must be effected at a duly called meeting of stockholders and not by written
consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
Notice Provisions</I>. Our amended and restated bylaws provide advance notice procedures for stockholders seeking to bring business before
our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our amended
and restated bylaws will also specify certain requirements regarding the form and content of a stockholder&rsquo;s notice. These provisions
might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors
at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions may also discourage
or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&rsquo;s own slate of directors or otherwise
attempting to obtain control of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Choice
of Forum</I>. Our amended and restated certificate of incorporation and amended and restated bylaws will provide that the Court of Chancery
of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting
a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended
and restated certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal
affairs doctrine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our shares of Common Stock is VStock Transfer, LLC. The transfer agent and registrar&rsquo;s address
is 18 Lafayette Place, Woodmere, New York 11598.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>National
Securities Exchange Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is listed on the NYSE American under the symbol &ldquo;AZTR.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="a_001"></A>Selling
Stockholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the Warrant Shares in order to permit the Selling Stockholders to offer these shares for resale from time to time. Except
for the investment in the Warrant Shares being registered hereunder, and, in the case of certain investors, their investment in (i) the
February RDO, (ii) the Letter Agreement Offering, (iii) the public offering that closed on January 16, 2025 (the &ldquo;January 2025
Offering&rdquo;) and (iv) the public offering that closed on July 25, 2024 (the &ldquo;July 2024 Offering&rdquo;), the Selling Stockholders
have not had any material relationship with us within the past three years. The shares of Common Stock issued in the February RDO, the
January 2025 Offering and the July 2024 Offering were registered separately. We are registering the Warrant Shares pursuant to the provisions
of the Letter Agreement we entered into with the Selling Stockholders on February 6, 2025, in order to permit the Selling Stockholders
to offer the Warrant Shares for resale from time to time. Pursuant to the terms of the Letter Agreement, the Company has agreed to use
its best efforts to cause the registration statement to become effective by the six-month anniversary of the closing of the Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the Selling Stockholders and other information regarding the beneficial ownership of the shares of Common Stock by
the Selling Stockholders and reflects holdings as of July 22, 2025. The second column lists the number of Warrant Shares owned.
Unless otherwise noted, all shares owned by the Selling Stockholders were acquired in the February RDO, the Letter Agreement Offering,
the January 2025 Offering and the July 2024 Offering. The third column lists the shares of Common Stock being offered by this prospectus
by the Selling Stockholders. The fourth column assumes the sale of all of the shares offered by the Selling Stockholders pursuant to
this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may sell some, all or none of their Warrant Shares in this offering. We do not know how long the Selling Stockholders
will hold the Warrant Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling
Stockholders regarding the sale of any of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 60pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of Common
Stock with respect to which the Selling Stockholders have voting and investment powers. The percentage of shares of Common Stock beneficially
owned by the Selling Stockholders prior to the offering shown in the table below is based on an aggregate of 20,676,354 shares of our
Common Stock outstanding on July 22, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Name of Selling</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares of <BR> Common Stock Owned <BR> Prior to Offering</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Maximum Number<BR> of Shares of <BR> Common Stock to <BR> be Sold</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares of<BR> Common Stock Owned <BR> After Offering</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Stockholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><SUP>&nbsp;</SUP></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percent</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><SUP>&nbsp;</SUP></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percent</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: left">L1 Capital Global Opportunities Master Fund</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1,521,492</TD><TD STYLE="width: 1%; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">7.36</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">561,492</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">960,000</TD><TD STYLE="width: 1%; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">4.64</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Alto Opportunity Master Fund, SPC &ndash; Segregated Master Portfolio B.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,821,492</TD><TD STYLE="text-align: left"><SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.81</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">561,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,260,000</TD><TD STYLE="text-align: left"><SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.09</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Anson Investments Master Fund LP</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,324,292</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.24</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">561,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,762,800</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.53</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Hudson Bay Master Fund Ltd.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,821,492</TD><TD STYLE="text-align: left"><SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.81</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">561,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,260,000</TD><TD STYLE="text-align: left"><SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.09</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumes
    the sale of all Warrant Shares being offered pursuant to this prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    1,521,492 shares represent the 561,492 shares of Common Stock underlying the Warrants issued on February 6, 2025 and 960,000 shares
    of Common Stock underlying warrants issued in the July 2024 Offering. The issuable shares of Common Stock related to the exercise
    of the Warrants are subject to a 4.99% beneficial ownership blocker; pursuant to the terms of the Warrants the beneficial ownership
    limitation can be increased to (but not exceed) 9.99%. David Feldman and Joel Arber are the control persons of L1 Capital Global
    Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed
    to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the Company&rsquo;s securities.
    To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial
    ownership of these securities except to the extent of its pecuniary interest therein. The address of L1 Capital Global Opportunities
    Master Fund, Ltd. is 161A Shedden Road, 1 Artillery Court, PO Box 10085, Grand Cayman, Cayman Islands KY1-1001.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    1,821,492 shares represent 561,492 shares of Common Stock underlying the Warrants issued on February 6, 2025 and 1,260,000 shares
    of Common Stock underlying certain warrants issued in the July 2024 Offering held by Alto Opportunity Master Fund, SPC- Segregated
    Master Portfolio B, a Cayman Islands exempted company (the &ldquo;Fund&rdquo;). The issuable shares of Common Stock related to the
    exercise of the Warrants are subject to a 9.99% beneficial ownership blocker. Ayrton Capital LLC is the investment manager of the
    Fund and has discretionary authority to vote and dispose of the shares held by the Fund and may be deemed to be the beneficial owner
    of these shares. Waqas Khatri, in his capacity as Managing Member of Ayrton Capital LLC, may also be deemed to have investment discretion
    and voting power over the shares held by the Fund. Ayrton Capital LLC and Mr. Khatri each disclaim any beneficial ownership of these
    shares. The address of Ayrton Capital LLC is 55 Post Rd West, 2nd Floor Westport, CT 06880. The address of Alto Opportunity Master
    Fund, SPC - Segregated Master Portfolio B is Suite #7 Grand Pavilion Commercial Centre, 802 West Bay Road, Grand Cayman, P.O. Box
    10250, Cayman Islands. The address of Waqas Khatri is 55 Post Rd West, 2nd Floor Westport, CT 06880.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    2,324,292 shares represent 561,492 shares of Common Stock underlying the Warrants issued on February 6, 2025 and 1,762,800 shares
    of Common Stock underlying warrants issued in the July 2024 Offering. The issuable shares of Common Stock related to the exercise
    of the Warrants are subject to a 4.99% beneficial ownership blocker; pursuant to the terms of the Warrants the beneficial ownership
    limitation can be increased to (but not exceed) 9.99%. Anson Advisors Inc. and Anson Funds Management LP, the Co-Investment Advisers
    of Anson Investment Master Fund LP (&ldquo;Anson&rdquo;), hold voting and dispositive power over the Common Stock held by Anson.
    Tony Moore is the managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam
    and Amin Nathoo are directors of Anson Advisors Inc. Mr. Moore, Mr. Kassam and Mr. Nathoo each disclaim beneficial ownership of the
    shares of Common Stock except to the extent of their pecuniary interest therein. The principal business address of Anson is Maples
    Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    1,821,492 shares represent 561,492 shares of Common Stock underlying the Warrants issued on February 6, 2025 and 1,260,000 shares
    of Common Stock underlying certain warrants issued in the July 2024 Offering. The issuable shares of Common Stock related to the
    exercise of the Warrants are subject to a 4.99% beneficial ownership blocker; pursuant to the terms of the Warrants the beneficial
    ownership limitation can be increased to (but not exceed) 9.99%. Hudson Bay Capital Management LP, the investment manager of Hudson
    Bay Master Fund Ltd., has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital
    GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims
    beneficial ownership over these securities. The principal business address of Hudson Bay Master Fund Ltd. is c/o Hudson Bay Capital
    Management LP, 28 Havemeyer Place, 2<SUP>nd</SUP> Floor, Greenwich, CT 06830.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="a_002"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders of the Warrant Shares and any of their pledgees, assignees and successors-in-interest may, from time to time, sell
any or all of their Warrant Shares covered hereby on the principal trading market or any other stock exchange, market or trading facility
on which the securities are traded or in private transactions. The securities may be sold or distributed from time to time by the Selling
Stockholders directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices
prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may
be changed. The sale of the securities offered by this prospectus could be effected in one or more of the following methods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
                                            brokers&#8217; transactions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">transactions
                                            involving cross or block trades;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                            brokers, dealers, or underwriters who may act solely as agents;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;at
                                            the market&#8221; into an existing market for our Common Stock;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            other ways not involving market makers or established business markets, including direct
                                            sales to purchasers or sales effected through agents;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            privately negotiated transactions; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            combination of the foregoing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the securities laws of certain states, if applicable, the resale securities may be sold only through registered
or licensed brokers or dealers. In addition, in certain states, the resale securities may not be sold unless they have been registered
or qualified for sale in the state or an exemption from the state&rsquo;s registration or qualification requirement is available and
complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may be considered &ldquo;underwriters&rdquo; within the meaning of Section 2(a)(11) of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may use one or more registered broker-dealers to effectuate all sales, if any, of our Common Stock. Such sales will
be made at prices and at terms then prevailing or at prices related to the then current market price. Each such registered broker-dealer
will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act. Broker-dealers engaged by the Selling Stockholders
may arrange for other brokers-dealers to participate in resales. Broker-dealers may receive commissions or discounts from the Selling
Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated,
but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage
commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA
Rule 2121.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
know of no existing arrangements between the Selling Stockholders or any other stockholder, broker, dealer, underwriter or agent relating
to the sale or distribution of the shares of our Common Stock offered by this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which
this prospectus forms a part to amend, supplement or update information contained in this prospectus, including, if and when required
under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this prospectus by the Selling
Stockholders, including the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by
the Selling Stockholders, any compensation paid by the Selling Stockholders to any such brokers, dealers, underwriters or agents, and
any other required information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our Common Stock covered
by this prospectus by the Selling Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the total expenses for the offering will be approximately $50,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Common Stock is currently listed on the NYSE American under the symbol &ldquo;AZTR.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="a_003"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thompson
Hine LLP, New York, New York, will pass upon the validity of the Warrant Shares offered hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="a_004"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements as of and for the fiscal years ended December 31, 2024 and 2023 incorporated by reference in this prospectus have
been so incorporated by reference reliance on the report of Grassi &amp; Co., CPAs, P.C., an independent registered public accounting
firm, given on the authority of said firm as experts in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC permits us to &ldquo;incorporate by reference&rdquo; the information and reports we file with it. This means that we can disclose
important information to you by referring to another document. The information that we incorporate by reference is considered to be part
of this prospectus, and later information that we file with the SEC automatically updates and supersedes this information. We incorporate
by reference the documents listed below, except to the extent information in those documents is different from the information contained
in this prospectus, and all future documents filed with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act (other
than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items
unless such Form 8-K expressly provides to the contrary) until the termination of the offering of these securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Annual Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000170147825000012/aztr-20241231.htm" STYLE="-sec-extract: exhibit">Form 10-K</A> for the fiscal year ended December 31, 2024 filed with the SEC on February 24, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Quarterly Report on <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000170147825000018/aztr-20250331.htm" STYLE="-sec-extract: exhibit">Form 10-Q</A> for the quarter ended March 31, 2025, filed on May 13, 2025;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000149315225002537/form8-k.htm" STYLE="-sec-extract: exhibit">January 16, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000149315225005103/form8-k.htm" STYLE="-sec-extract: exhibit">February 6, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000149315225005106/form8-k.htm" STYLE="-sec-extract: exhibit">February 6, 2025</A> (both filed on that date),
    <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000149315225007717/form8-k.htm" STYLE="-sec-extract: exhibit">February 20, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000164117225006043/form8-k.htm" STYLE="-sec-extract: exhibit">April 24, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000164117225008331/form8-k.htm" STYLE="-sec-extract: exhibit">May 2, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000164117225015636/form8-k.htm" STYLE="-sec-extract: exhibit">June 18, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000164117225016073/form8-k.htm" STYLE="-sec-extract: exhibit">June 23, 2025</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000164117225017786/form8-k.htm" STYLE="-sec-extract: exhibit">July 3, 2025</A> (other than any information
    under Item 2.02 or Item 7.01 of each incorporated Form 8-K);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our definitive proxy statement filed on <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000149315225002139/formdef14a.htm" STYLE="-sec-extract: exhibit">January 14, 2025</A>;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    definitive proxy statement filed on <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000164117225012879/formdef14a.htm" STYLE="-sec-extract: exhibit">May 29, 2025</A>, as amended on<A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000164117225015581/formdefa14a.htm" STYLE="-sec-extract: exhibit"> June 18, 2025</A>; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    description of our Common Stock set forth in our registration statement on Form <A HREF="https://www.sec.gov/Archives/edgar/data/1701478/000149315223017652/form8a12b.htm" STYLE="-sec-extract: exhibit">8-A12B</A> filed with the SEC on May 16, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any statement in this prospectus is inconsistent with any statement that is incorporated by reference and that was made
on or before the date of this prospectus, the statement in this prospectus shall supersede such incorporated statement and the incorporated
statement shall not be deemed, except as modified or superseded, to constitute a part of this prospectus or the registration statement.
Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete and, in each
instance, we refer you to the copy of each contract or document filed as an exhibit to our various filings made with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Azitra,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21
Business Park Drive,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Branford,
Connecticut 06405</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Corporate Secretary</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
(203) 646-6446</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><A NAME="a_006"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of Common Stock offered
by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set
forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and
regulations of the SEC. For further information with respect to us and our shares of Common Stock, we refer you to the registration statement,
including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents
of any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration
statement, please see the copy of the contract or document that has been filed. Each statement is this prospectus relating to a contract
or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an Internet website that contains
reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website
is www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we file annual, quarterly and current reports and proxy statements and other information with the SEC. Our SEC filings are
available on the SEC&rsquo;s website at www.sec.gov. These filings are also available free of charge to the public on, or accessible
through, our corporate website at www.azitrainc.com. Our website and the information contained on, or that can be accessed through, our
website is not deemed to be incorporated by reference in, and is not considered part of, this prospectus. You should not rely on any
such information in making your decision whether to purchase our Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not authorized anyone to give you any information or to make any representations about us or the transactions we discuss in this
prospectus other than those contained in this prospectus. If you are given any information or representations about these matters that
is not discussed in this prospectus, you must not rely on that information. This prospectus is not an offer to sell or a solicitation
of an offer to buy securities anywhere or to anyone where or to whom we are not permitted to offer or sell securities under applicable
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to 2,245,968 Shares of Common Stock Underlying the Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form424b3_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> July 23<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form424b3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !G 8 # 2(  A$! Q$!_\0
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MM?\ CZA_ZZ+_ #K[HT3_ ) &G_\ 7M'_ .@BOA>U_P"/J'_KHO\ .ONC1/\
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MW\,:/!I6EWRQ6T0[#EF[LQ[L?6@#T?3-+MM'TV"PL8EAMH$VQHHZ?YZU;4%
M<G/L*X(?&;P/C_D+?^.TA^,W@CMJH^NV@#T#/.*^,_BO_P E2\0?]?/_ +**
M^J_#7C#1/%OGMHUUYXM\>9[9_P#U5\J?%?\ Y*EXA_Z^?_910!REK_Q]0_\
M71?YU]T:'_R -/\ ^O:/_P!!%?"]K_Q]0_\ 71?YU]T:'_R -/\ ^O:/_P!!
M% ' ?'O_ ));<_\ 7U#_ .A5\GU]8?'O_DEMQ_U]0_\ H5?)] 'NG[-W&JZN
M>WDC^8KZ)!YQ7R3\'O&]CX*\07,VIAQ9W,/EET7)5L@C^5>^6OQ<\'WEU;VU
MMJ1EGN'$<:!><GUH \[_ &DQG^PCZF3^E> CKBO??VD3D:$>Q\PC\A7@7\5
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' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>form424b3_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b3_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '$ W$# 2(  A$! Q$!_\0
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M3/C_ %#Q)X-TO]H_Q3\/O"'B*UT@DV'AC*_V"NW@$$;@<L"#M&#EL?8NF?\
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MOX6\-_L__"_XK?LWG4O%Q^(OQ*TSPU=WG_"/,R^%--T35T3QWI&MHQ/D^(@
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MC\;_ !K\#?VMYO#OPY\2ZCK7@_\ ;P/Q:7P1JUB=-_X3WPOH.LEC_8A QK_
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M^E^)_P#A"+/PWC4[#2_[:\/]=#&<^'1[=B:_1W_@HY\/O&VF^%/V,OBKX3\
M>(O%WA?X ?$OPQXH\>^'_ UE_:/B>Q\,)HBQ-_8NB<;G4QE&/\("*<8%?MD+
M>V/2$?K_ /%4OE#RL9'V<#..^/3IT_3\*Z/[1_#U_P CQL+P6L+>S6O9KO<_
MG]\&W?Q%_: _X*(Z_P#$NQ^%GC[X;_#[Q/\ LF^*/!7AKQ9XXT?5]+%]J;OA
M=8&-H\/[=P0#[S# RS]?DF;Q3XQ^"7_!.C]HC]D/QS^SUXNN?'/A<>/+R]\;
M_P!D$_#*_P!*UW6C_P 7._X3?D YSR #Q@G Q7]5]QIME>VTT$T(^SW-K]D8
M'!RIW# 'KD\$\9'I7Y@ZY_P2K^#6OWNKZ9<?$WXZ+\,/$&L#6/$GPE;Q_JQ\
M$:Y(55A ZYR-%()_=C< 0?GR17?ALR5DL9LMDNG+LE;MV^3T.#$\-XS"ZX+=
MWOY_UU/?_P!B&S-Y^Q=\!['S_P#2+KX*>%[$W0Z\Z+C/KWY'<9ZFOQ4^'"?$
M?]FOX%?M>?L?>*?V;_B%XT^)_B_Q)\4_$_A#7O#OATZEX7\?Z5X@ &A:TVM9
M&2N-RD@X.0,9-?TJ>&?"VB>"?#V@^%/#.GVVG:#X<L]/TC2-,M3A+#3X]D03
M&2<$*"!P#M+#[Q VOLRAVG.WC/'V<L2/U('^<=Z\]9A;&2:6K=[7ZMV2\MEI
MTUT/7Q/#BQ."RG!W7NWYGV5M='?H]'OU5M#^4W7OV=OC%9_ C_@GO\6M5\.?
M&.V\,?"7PUXGT7XD:3\,M'/_  LSP'JFO:V?^)WH>AD8YY[G\*^U?V9?V1O@
M_P#&OP/^T]?:%8_M'?\ %^?"/_"%:UX@^/=H=-.OZEH0)T+64T/GY_"7B,;L
M8.0".,Y'[O\ D1PPS0PH@!SC%LN#G'0\ @8/3&.O6EB@CM^(6 ]\$_EQ^M=.
M(SJ3O[KWTM>]M/+1[_@<&%X(PF$?_(V;\K/M_P $_G7_ & /@U\?OBS\5/%O
MCWX^^'M;\,ZS^SM\+]2_9O\ A5=^*[+/]H;3K^B/XRT3((&8TT8$G&!G:0Q6
MOD'X>_LW_P#"*^%]?_9E_:,\*?MG_P!OW7CSQ2;SPG\)M(_M+X0^+-+UW6AK
MP\:#7,?\4_D9))8'(P <G']=/D'_ )XVOYM1#$!U@QTSS]<\Y_KZ4O[;U;YN
MW3M\^MQ?ZDX+1>OX_CTTW/PE^*OP;\5+^WG^S!X>\(Z'XUN/"VD_LE>/OA_:
M?$.[M,C0-2&BG0=".NZ[Q_Q46W!/'!S7SGX3USQ_\+?V,?'_ /P3\UG]EOXD
MZ[\;=7G\<^%M'N;/PZ=4\ ^+UUS6W=/&^L>-PWEJS^;EG"%I%6(;@J\_TRRV
MEN?^6/\ C[<>W;U[FD^RKYWG^2,X_#U_+_\ 5TK'^T;]-M>IT_ZI/6V;M-W6
MW1]+._;1W/YC_BQX7\5?LX_'/_@EQX6\4^%M2^+?B?X2_"SQ4GB_P]I-D=1U
M._*:-L;6M#W8S_PB3JWL1T)');\6_#'Q,_:%UK]NW]J/P=\%_'W@GX?ZW^SS
MI?PC\,:1K_AH:7XX^)7B5=:QK>L+H&2=J+M0$DG&-S$Y-?N[\0OV6?AW\2?C
MU\'_ -HG6KW6HO&OP9LM6LO#5E9W6S2[Y-:!W'6$"D-MR" JE>>_ /TM%:0C
MI",CKG]>XQG_ /4>M;_VCY:_/[E^?_!//P_!5KI9N[7O;2^B_P""[V>MS^<_
MXO\ P?\ %5W\)O\ @DSX<@^%>N:E;^%_'OA>]\7Z3:^'/[3&@@:(,?VWV&<'
MC!)//3BM;]H+X _%7XF_ME?MO>'/!7A;6[8^//V/=)T3PAXB-H--\,Z]JQ('
M]B'7>F2W&!W/'H?Z&_)_=?K[?SST'7],T>3!#VMN,GMS_+I_GG-)9W;[7?IW
M=^_R]#T,3P5@_P 5^"M_D?RW_LZ_ WP/\0M4_9_^%?Q4\.?MPVWCCX7ZQI=[
M_P ([JVD?\6S^&GBC0NG]AZX!_R+I_'^A^^_@YX \51_\%4_VJ_&FK>"=4A\
M+ZC\'?"6G^&_%][H^-.U$H%&N:1HNN#'S$@.PX&<C')!_9(00?OFAA@$Y&/M
M%MMZX!'."<CD'DCKGW<(A')D0V_GL.#R#_+@>_.*PQ.9?6VOZ_K_ "##<)X3
M!][73^=FE^#9_*/>_"7XM6?[&_Q7GL/A'XVN;GP;_P %!S\3KSPI::-K/_"3
M7_@+0M:U[.LZ'HG_ #'^<'!QDC_9X_IL^$_BZR^(?P]\(^-K#2]=T73_ !!H
MVGWUII/B"S;3-6L%<, NKZ1O41L& /!.,# 3@CU/[' .L=O^7^ J#R3_ *C_
M )8?K_G]<>W%&)S+ZW^?;^O\COR3AQ95C'C$[NUG:^FZ_5V-*'_4CZ'^53U7
MAB\F,CO_ "]/Z58KSSZ@**** "BBB@ HHHH ***9O'H?T_QH ?13-X]#^G^-
M/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX:0\$_\ 0$\:_P#A-M_\775>=<?\]Q_G\:/.N/\ GN/\_C0!Q_\ PT7X,_Z
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MW?D^&L_CU'TX/K4__#17@C_H"^-?_"9_^RKH/.N/^>X_S^-6/.N/^>X_S^-
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MX:0\$_\ 0$\:_P#A-M_\775>=<?\]Q_G\:/.N/\ GN/\_C0!Q_\ PTCX(_Z
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M='_#2'@G_H">-?\ PFV_^+KJO.N/^>X_S^-5_.N/^>X_S^-!SG._\-(>"?\
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M$\:_^$VW_P 71_PTAX)_Z GC7_PFV_\ BZZKSKC_ )[C_/XT>=<?\]Q_G\:
M.5_X:0\$_P#0$\:_^$VW_P 71_PTAX)_Z GC7_PFV_\ BZZKSKC_ )[C_/XT
M>=<?\]Q_G\: .5_X:0\$_P#0$\:_^$VW_P 71_PTAX)_Z GC7_PFV_\ BZZ/
MSO\ IO\ Y_[XI/.N/^>X_P _C0=!SO\ PTAX)_Z GC7_ ,)MO_BZ/^&D/!/_
M $!/&O\ X3;?_%UU7G7'_/<?Y_&CSKC_ )[C_/XT'.<K_P -(>"?^@)XU_\
M";;_ .+I?^&D/!/_ $!?'G_A,'_XY74^=<?\]Q_G\:/.N/\ GN/\_C0!RW_#
M2'@G_H"^//\ PF#_ /'*/^&D/!/_ $!?'G_A,'_XY74^=<?\]Q_G\:/.N/\
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M!']@L[: 0H 9LX=@6 4': #^EG^V=#GNH+'^W/#?]HC2!K-G:'5]'_M/^R\
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M#_K8/K_05X]\,/\ D,?&#_L?/ZM7K,/^M@^O]!7DWPK_ .0S\8,SVW_(^?\
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MICTQ[]/>D\Z<_P#7P?\ CS_3GWS^II<0_P#/:W_\##_C1_VWM_\ P+_^M0=
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M.OY\YH_])?\ /^?_ +*C$/\ SVM__ P_XT?]M[?_ ,"__K4 !\^:+R)Y^?\
M(X_QZ>GK5CSI_P#EA/\ 9?LO_'GCT_R,9_KD57_[;V__ (%__6HQ#_SVM_\
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MH L>=/-_K_\ /;^6?\\D\Z<RW%QY_P#I%T._&<__ *_QJOB'_GM;_P#@8?\
M&C$/_/:W_P# P_XUS@6/.G\GR//.>OZ^GK^O;WI89IH8OW'3^?\ +\?_ *_%
M;_MO;_\ @7_]:C_MO;_^!?\ ]:N@"QYW_'Q!Y_\ H]T/],Y]?\^OUI/.N/\
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M10 S_6)_O#^O_P!;\/>J/]G6/_/K;?\ ?/\ ]>M&B@#._LZQ_P"?6V_[Y_\
MKUX[K'P*^'.LZQJ&MRV&IP:CJC?:[TVFLZMI_P!M;&#O"L/Q"\\\@5[7/V_#
M^M?(?Q&_;J_8\^$'BW4/ /Q3_:%^%W@CQOI84ZKX?\1^)=*TW5;#< 3O1@I4
MCT;+>NTC% 'I?_#/7PY_YX>(_P#PH]:_QH_X9Z^'/_/#Q'_X4>M?XU\__P##
MS?\ X)^?]'8?![_PL?\ [&C_ (>;_P#!/S_H[#X/?^%C_P#8T ?0'_#/7PY_
MYX>(_P#PH]:_QH_X9Z^'/_/#Q'_X4>M?XU\__P##S?\ X)^?]'8?![_PL?\
M[&C_ (>;_P#!/S_H[#X/?^%C_P#8T ?0'_#/7PY_YX>(_P#PH]:_QH_X9Z^'
M/_/#Q'_X4>M?XU\__P##S?\ X)^?]'8?![_PL?\ [&C_ (>;_P#!/S_H[#X/
M?^%C_P#8T ?0'_#/7PY_YX>(_P#PH]:_QH_X9Z^'/_/#Q'_X4>M?XU\__P##
MS?\ X)^?]'8?![_PL?\ [&C_ (>;_P#!/S_H[#X/?^%C_P#8T ?0'_#/7PY_
MYX>(_P#PH]:_QH_X9Z^'/_/#Q'_X4>M?XU\__P##S?\ X)^?]'8?![_PL?\
M[&C_ (>;_P#!/S_H[#X/?^%C_P#8T ?0'_#/7PY_YX>(_P#PH]:_QH_X9Z^'
M/_/#Q'_X4>M?XU\__P##S?\ X)^?]'8?![_PL?\ [&C_ (>;_P#!/S_H[#X/
M?^%C_P#8T ?0'_#/7PY_YX>(_P#PH]:_QH_X9Z^'/_/#Q'_X4>M?XU\__P##
MS?\ X)^?]'8?![_PL?\ [&D_X><?\$_?^CL/@W_X5^D?_%4 >_?\,^_#-9;>
M:XL-2U.&VR19:KK&KZCIV.N<,V./7=[8S71^./A-X(^(,.CP^*=*^T6^@W?V
MW1S:71T_[ >QP"/Q&/;(Q7S+_P /./V /^CM?@Q_X6.D?XT?\/./V /^CM?@
MQ_X6.D?XT >\?\,[_#KS&(@\1?Z3G[3_ ,5+K&#QQ_'@Y/J5&!V'5W_#/7PY
M_P">'B/_ ,*/6O\ &O!?^'G'[ '_ $=K\&/_  L=(_QJ'_AYO_P3\_Z.P^#W
M_A8__8T ?0'_  SU\.?^>'B/_P */6O\:/\ AGKX<_\ /#Q'_P"%'K7^-?/_
M /P\W_X)^?\ 1V'P>_\ "Q_^QH_X>;_\$_/^CL/@]_X6/_V- 'T!_P ,]?#G
M_GAXC_\ "CUK_&C_ (9Z^'/_ #P\1_\ A1ZU_C7S_P#\/-_^"?G_ $=A\'O_
M  L?_L:/^'F__!/S_H[#X/?^%C_]C0!] ?\ #/7PY_YX>(__  H]:_QH_P"&
M>OAS_P \/$?_ (4>M?XU\_\ _#S?_@GY_P!'8?![_P +'_[&C_AYO_P3\_Z.
MP^#W_A8__8T ?0'_  SU\.?^>'B/_P */6O\:/\ AGKX<_\ /#Q'_P"%'K7^
M-?/_ /P\W_X)^?\ 1V'P>_\ "Q_^QH_X>;_\$_/^CL/@]_X6/_V- 'T!_P ,
M]?#G_GAXC_\ "CUK_&C_ (9Z^'/_ #P\1_\ A1ZU_C7S_P#\/-_^"?G_ $=A
M\'O_  L?_L:/^'F__!/S_H[#X/?^%C_]C0!] ?\ #/7PY_YX>(__  H]:_QH
M_P"&>OAS_P \/$?_ (4>M?XU\_\ _#S?_@GY_P!'8?![_P +'_[&C_AYO_P3
M\_Z.P^#W_A8__8T ?0'_  SU\.?^>'B/_P */6O\:;_PSM\./^>/B/\ \*76
M/\:\!_X>;_\ !/S_ *.P^#W_ (6/_P!C2?\ #SC_ ()^_P#1V'P;_P#"OTC_
M .*H ]]B_9]^%D,MO/<:5J6H"W/VM;6\UC6-1T[/(S@DAAQD#@G'W2*ZOQQ\
M,?"'Q(TFQTGQ=I0N;&UNS>K:VV=/4..FX @D9 S@@D9QC@U\K_\ #SC_ ()^
M_P#1V'P;_P#"OTC_ .*I?^'G'_!/W_H[7X-?^%CH_P#C0![]%^SM\-!TMM<_
M\*35SGCW=?3U_G1_PSM\./\ GCXC_P#"EUC_ !KP'_AYQ_P3]_Z.U^#7_A8Z
M/_C1_P /-_\ @GY_T=A\'O\ PL?_ +&@#Z _X9Z^'/\ SP\1_P#A1ZU_C1_P
MSU\.?^>'B/\ \*/6O\:^?_\ AYO_ ,$_/^CL/@]_X6/_ -C1_P /-_\ @GY_
MT=A\'O\ PL?_ +&@#Z _X9Z^'/\ SP\1_P#A1ZU_C1_PSU\.?^>'B/\ \*/6
MO\:\%_X>;_\ !/\ _P"CL_@M_P"%<G_QNO;/@S^TI\!_VA[?5[WX'_%GP3\3
MX= N5L?$7_"(ZSI.I7VG/M*A=80$F,+C VJF58#DDX +W_#/7PY_YX>(_P#P
MH]:_QH_X9Z^'/_/#Q'_X4>M?XU[ML'J?T_PHV#U/Z?X4 >$_\,]?#G_GAXC_
M /"CUK_&C_AGKX<_\\/$?_A1ZU_C7NVP>I_3_"C8/4_I_A0!X3_PSU\.?^>'
MB/\ \*/6O\:/^&>OAS_SP\1_^%'K7^->[;!ZG]/\*-@]3^G^% '@,O[.WPY/
MD?Z/K@@&/^9EUCZCC)P#VSC\!T]0LO"NAZ;HUOH5A86VFZ/:6GV*SM+4?\>'
M?@^N>Q^A R#77;!ZG]/\*-@]3^G^% 'SM:?LS?"O3(;B'3=*U+2K:YO/MIM]
M+UG5U4GCC'F$C/H>.V3UK3_X9[^''_/MKO\ X4NL?XU[CY'O^O\ ]:I=@]3^
MG^% 'A/_  SU\.?^>'B/_P */6O\:/\ AGKX<_\ /#Q'_P"%'K7^->[;!ZG]
M/\*-@]3^G^% 'A/_  SU\.?^>'B/_P */6O\:/\ AGKX<_\ /#Q'_P"%'K7^
M->[;!ZG]/\*-@]3^G^% 'A/_  SU\.?^>'B/_P */6O\:/\ AGKX<_\ /#Q'
M_P"%'K7^->[;!ZG]/\*-@]3^G^% 'A/_  SU\.?^>'B/_P */6O\:/\ AGKX
M<_\ /#Q'_P"%'K7^->[;!ZG]/\*-@]3^G^% 'A/_  SU\.?^>'B/_P */6O\
M:/\ AGKX<_\ /#Q'_P"%'K7^->[;!ZG]/\*B\CW_ %_^M0!X=_PSU\.?^>'B
M/_PH]:_QKKO"'P^\(> ["ZA\-:5]GAU*Z^V7ERV=1U#4'X.6?:Q 'L#@9R"<
M8]#\CW_7_P"M4NP>I_3_  H \.UCX!?#C6O$U_XPOM*U!/$^IC;=ZG::QJX/
M X"X8* !@  8'3@5!_PSM\./^>/B/_PI=8_QKWNB@#P;_AGKX<_\\/$?_A1Z
MU_C1_P ,]?#G_GAXC_\ "CUK_&O=M@]3^G^%&P>I_3_"@#PG_AGKX<_\\/$?
M_A1ZU_C1_P ,]?#G_GAXC_\ "CUK_&O=M@]3^G^%&P>I_3_"@#PG_AGKX<_\
M\/$?_A1ZU_C1_P ,]?#G_GAXC_\ "CUK_&O=M@]3^G^%&P>I_3_"@#PG_AGK
MX<_\\/$?_A1ZU_C1_P ,]?#G_GAXC_\ "CUK_&O=M@]3^G^%&P>I_3_"@#PG
M_AGKX<_\\/$?_A1ZU_C1_P ,]?#G_GAXC_\ "CUK_&O=M@]3^G^%&P>I_3_"
M@#PG_AGKX<_\\/$?_A1ZU_C6IX9^#/@+PKJ8UW3]+NY]86T%I:W6IW>J:FUH
MH!RH,IPH)P&8@' (4@L&'KOD>_Z__6J78/4_I_A0!Y/XW^%'P_\ B$-(/BG2
M_M/]DG[7I.V[:P*M@<$+SQG/0=>PK!_X9[^''_/MKO\ X4NL?XU[CY'O^O\
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M\.?^>'B/_P */6O\:/\ AGKX<_\ /#Q'_P"%'K7^->[;!ZG]/\*-@]3^G^%
M'A/_  SU\.?^>'B/_P */6O\:/\ AGKX<_\ /#Q'_P"%'K7^->[;!ZG]/\*-
M@]3^G^% 'A/_  SU\.?^>'B/_P */6O\:/\ AGKX<_\ /#Q'_P"%'K7^->[;
M!ZG]/\*-@]3^G^% 'A/_  SU\.?^>'B/_P */6O\:/\ AGKX<_\ /#Q'_P"%
M'K7^->[;!ZG]/\*-@]3^G^% 'A/_  SU\.?^>'B/_P */6O\:/\ AGKX<_\
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M5K=S!?VITH^,/"5Y>#_A&?B5X84AM;T;6_1E8!E8$%6 88(!K_3,_P""?O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIXLO?^$;U/Q;X7_YCNM:YH?7_A(O"6 /\<BN<#Z _9=_X+&:Y^QS^RW^R?\
M!?X2?\))_;/PO^-?CSQG^T)X3N[+1O\ A&OB9\+O'.?^)+H?<^(N21UQ^)KY
M?^(7[<GASX>^//VJ-*_97\&^&_%OP7_:5UC5-:_M;]H3P'_PDGQ?\!ZKKO\
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M[3?B#X+>.+?Q)<^'_ASX/\>>)_'EI\/;S^TO$U_JG@7IHNAZYQ71]9\_Q_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !_P L?^GG_P"O^77_ #FOJ?\
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MT)-_P7%_8WA_9#TG]K2:W^(UM;Z]\1]3^#&C_!6^\-&Q^+^H_&31G/G>!5T
MME-?PB'[Y3+ !#Y9S]?_ +#'[?WP(_;^^'6O^/O@]/K6FZKX,\0OX.^(_P /
M_%UD=,\:^ /$\8!.B^(-(RQC?#,5?@';)G! S^%?CS_@A7\>_&'P-\46'_"<
M?"^Y^,_A7]OWXH?M@_"S3/$2ZTO@+Q9X8\=:UX@!\%>.)-  \2DCP]K>Q@A8
MJ_R, <@?KG_P3,_9#^(G[+/PN\;R?&'PK\$O"?Q5^*7C"3Q/XGTOX$66M_\
M"*Z<L?R:,KZ]XBUV7Q'KH WAA(T98KM4D%MH<Y^H-6*@A_U(^A_E4]!T!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?YB__!?B$?\ #UG]H#_L#^%\]_\ F"^O;\,9Z5_IP3]OP_K7^9=_P7KT;Q'=
M_P#!5/X_SV'A3Q;J-M<Z-X6Q=:1X;UC4=,OO^)(./[<'  X'' ]A0!X1^S'^
MUI^S+\']+^$_B/QC\%OBC;?'CX(WFJ7OAOXF_!'QAHW@K3/B7I?;1?CAH?\
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M ,SE6/\ A&_&/_0F^/O_  C]9_\ F:H.<_1#QM^WMX4\82_&C_BW/B33=/\
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MXB_X2/G_ .O7SA_8/C#_ *$;Q_\ ^$=K/_S.5!_PC?BK_H1O&W_A'ZQ_\S=
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M(W:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ()O]2?H/Y5P.I^ O >L7WV_5/!/A/6
M=0N ?M=UJOAW1-3U)@!QN9XV;'7<1N]>37>S]OP_K7F&L_&+X6^'-2N-#\1?
M$CP'X?UBW0?;-)U?Q=HFF:C8%N<-%++&X/8A@"",$YR* +?_  JGX9_]$\\
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M':)_\163_P +X^"G_1:/A7_X<#P=_P#+^C_A?'P4_P"BT?"O_P .!X._^7]
M&M_PJGX9_P#1// /_A':)_\ $4?\*I^&?_1// /_ (1VB?\ Q%9/_"^/@I_T
M6CX5_P#AP/!W_P OZ/\ A?'P4_Z+1\*__#@>#O\ Y?T :W_"J?AG_P!$\\ _
M^$=HG_Q%'_"J?AG_ -$\\ _^$=HG_P 163_POCX*?]%H^%?_ (<#P=_\OZ/^
M%\?!3_HM'PK_ /#@>#O_ )?T :W_  JGX9_]$\\ _P#A':)_\11_PJGX9_\
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M !%9/_"^/@I_T6CX5_\ AP/!W_R_H_X7Q\%/^BT?"O\ \.!X._\ E_0!K?\
M"J?AG_T3SP#_ .$=HG_Q%'_"J?AG_P!$\\ _^$=HG_Q%9/\ POCX*?\ 1:/A
M7_X<#P=_\OZ/^%\?!3_HM'PK_P##@>#O_E_0!K?\*I^&?_1// /_ (1VB?\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8_0?7^AK_,:_X+Y7FJP?\
M!5[]H#R-<UNVM_['\+?Z)::QK&F_\P7/Z_I7^G17^8Q_P7X_Y2O?M$?]@;PS
M_P"F84 ?C_\ VEK?_0Q^+?\ PI=;_P :7^T]<_Z&/Q)_X4FLU][?L<_\$W_C
MA^VQ\*OCA\6_A7JOAO1-'^"-G_IMGXA/_$S\>:H?^)]_8NAY_P"9BY_R:[#]
MA7_@FS??MX>$O$&N>'/VJ/@5\'/&'@W^U+WQ'\)_B;_R/-AX7T,_\3WQISG_
M (IWW[]!0!^;']I:W_T,?BW_ ,*76_\ &C^TM;_Z&/Q;_P"%+K?^-?M=H_\
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MT?VEK?\ T,?BW_PI=;_QJM10!9_M+6_^AC\6_P#A2ZW_ (T?VEK?_0Q^+?\
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MO_$I;4RR@?VNO(,>UL-U/*Y)R*_,/]@7]LW]MSX\?$_X83_%/]LC_@G/X_\
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M\'Z_^WY\4/V8_'EWX1\(:WJ&J:?X$T//]A:-H6BK@Z_XCY/((8Y()[4[1O\
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M[*_[./CKX,?LXVGP<O6;4_B5XIU_0O#WA]=:\;:V3_Q3OADKH2D^%4 3.]R
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M?%'A'PL$0:YXU\0Z)G_B1_#Q9/,(\3$&(JRAXV*Y/Y]? 7_@C+^UGX=\&_\
M!4/P=XIF\/>&_P#AL_X1> ]"^%NK>)/B*_Q7\2Z?XI\" 9T;QMKLBJ7C.>)4
MW1DYPQVMMXCXM?\ !(3_ (* >-M4_9^_:,G^&O[+7Q'^-^E_LQ^%/V5OC!\$
M?$/C[QCX;^&>@Z5X)8^'O#OC70]=\/\ _(P"3P\-OC/POR'(VJ3P#T ?L)^T
M#_P6L_8Q^#NB_#?^Q/$OBWXLZS\9/A;JGQ:\'#X2>#M9\<+H/P_32F\OQIXY
M.A OH&@MK>R*5R3R"R8(!KTK_@EA^V5X[_;*_8;\'_M1_%RRT.TUG7[WQY>
M^%+4_P!F?\(QHNMZXNA:NF6PH?P\J951AF))7>Y8_E_J?_!+W]N7]EKXG^&/
MBW^PIX4_9?U>^^)W[+:_LW_'?X9^.;[6M)\"_#=DVR#6_A3M8-_PC6\%#X4;
M'F;7!5HF!?\ 2G_@EO\ L?\ QA_9"_X)Y^'?V;/C/+X;N/BO96OQ0?6[GPC>
M!O#3ZIXZUOQ!KBC12<E5#ZTW09W(1D;6H.<X3X5?\%O?V/OC+HWQ?\1^ _#_
M ,<]=\+?!L7UCXC\167PHUJ]T_7O%,6LG0CX,\%%'(\2>(&DP?+41HJ[E.\$
M@Z47_!:W]CRS\ _%#Q1XVN/'OPV\7_"7QCX7^'GB_P"#GC;PT=+^)B>./'7/
M@71%T+<<OXKP0C#:$R&"G:5?XF\+_P#!-O\ ;Z^%W_!*"^_9:^#/Q \$_"S]
MHZ[^.OCSQ]JU]H-]HR+XL\#>(?'.MZVNA'QNWA\?V#XEF\/O&D7BD1E@RLA<
M-(J-\H?"K_@BK^U7X/T_]MF#QA\-/@W\4O"_[1E[\&O$^C_#[XQ?$?6O&_B7
M41X%*?V]H^L_%4#_ (2;0?B GF+_ ,(7XM4LB$D.RE7"AOB>MO/S[GZ<?M1?
M\%:XM)_X)[?M(_M6?LX^$]8\/_$3]G[5-+T3QCX)^-_AO6O#?_"+:K)O$L;0
MD%/$$878%_X1625G!<$+M#2>\?L._P#!63]FS]MKQOJ?P6\#'QKH?Q@\,> O
M"_C_ %;P[XW\&ZSX)'BS2M<&=:UOP0-?;/B#P^DF65E*<-@C*HZ_DCH?_!'7
M]LF#]@;]NC]GN'6]-TW_ (:4\1^!-9^!'P(\;_$@>.-,^"NF:'L.NIKOQ3R7
M\0,X*D*JG=@=#L!_3GP3^Q'\8?#G_!2+X,?M3SV_@JV^$_@/]B;2_P!GW6/L
M=V1XF/CPG0AM713@?\(\"K9 ;*\$X!4D,#]DH9O-_P _YXZ]JL56BBQ&!ZC\
M/\<?J*6#O^/]*#H+%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7^8O\ \' '_*5C]H?_ + _A?\ ],M?Z<W\'_ ?Z5_F$?\
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M^.?"7@/XL#0/["UKP/KGB#_F8L?\RMCI^8_G_P#[8TKG_3NG_/WW[_\ U_\
M <40Z]8PRV\\&JW-M<6IR;NT/]FZF/\ /X?UH _9#_@JY#X ^'NO?L+_  0T
MKQ_XD^+7_"A_@GI6B^/-6\0ZO_:7CFP_XG7_ "!-<US_ *&(>M?>&O?\%7/V
M'_!/PE_X17X.V_C^YUC_ (61\&_&FC^$[OPWK/\ :=AI?@7_ )#NB^./''B#
M_D8/$77//0_E_+__ &]8S2W%Q/KES<W%U_Q^7=W>:SJ6I^O'N1Z>O%+_ &QI
M7_00'YC_  H _??7OVQOV&/"MKX/L?AE\3?C]K>H:7^UIX\_;#UB[N]'_P"$
M<U._\4:[HN@?V%\,OT_XK?Z?@>?\=_MU?LH?M":K^TA8^/\ QQ\;/@5I_P"U
M]H_@/Q/X]\0_#VS_ +2U+X+>// V/^+8Z&?^B=^+/[#]J_!_^V-*$1@GGMOQ
M/I_G^OUL3:QI4W^OOL<_7G_/KCKWH^L^?X__ &P']*'A#_@JY^R]>>//$'B/
MQ3??%KP3I_@WXD>%M:^%=W:67]I>)OB7I>A?#'7_  '_ &UXX_Z%_P 1?\3P
M^GXU\W_"O]O?]G.'1O@OXX^+?Q&^/WA+XD?LE_$CXR?$'P?X(\$WFLZEX8_:
M'TOXKZU_;VA?\)SKGI_^JOP__MC0^U];'K]LS[_3V/\ 6C^U]*_U'V[_ #]?
MTH#ZMY?A_P#:G]+'[17[5WP!^&^C?!?XTZYX^\?ZE\8/&7[&>J^&-&_9E\/8
MU+X&_P#%=?\ 0<S_ ,4QX?/A/_(SS7Q_\5/V_/A7XV_X;!TJ#7/B1<Z1\;OV
M8_@W\)/AOX>U;^V?[,T'QYX%_P"0[_Q(QGH.M?C/_;UCBX\_5;FYM_\ I[_K
M[TO]L:5_T$!^8_PH GA@\F+R/3_C\_7(X_SC\ZL50_MC2O\ H(#\Q_A1_;&E
M?]! ?F/\* +]%4/[8TK_ *" _,?X4?VQI7_00'YC_"@"_15#^V-*_P"@@/S'
M^%']L:5_T$!^8_PH OT50_MC2O\ H(#\Q_A1_;&E?]! ?F/\* +]%4/[8TK_
M *" _,?X4?VQI7_00'YC_"@"_15#^V-*_P"@@/S'^%']L:5_T$!^8_PH OT5
M0_MC2O\ H(#\Q_A1_;&E?]! ?F/\* +]%4/[8TK_ *" _,?X4?VQI7_00'YC
M_"@"_15#^V-*_P"@@/S'^%']OZ5_S_C]* +]?>O_  3N_P"">GQG_P""CGQG
MM_AI\-(;C0_ ^@WNE7GQ3^*]W9_\2WP+X8/W%49RWB5CPJCEC@#DU#_P3L_X
M)\_&'_@I)\:-/^&GPTANM$^'VEC[;\5/BQ=V6?#/A+PN3@:( !EO$9. % R3
MC SQ7^F'^Q_^QU\%/V(?@GH/P/\ @;X7L]$\/Z5;1_VIJA"_VEXJU9B5UG6]
M<=OO32,3]T@+E45<Y>4.<;^QU^R#\&/V(?@EX9^"'P1\.6>C:'H-F&U?4\-_
M:OBKQ+C_ (G.MZ[JY1GDE>0'@A @4*JF16,GUO%$ /TX_P _F?P%$46(P/4?
MA_CC]15FN@#/F_YX8_SQ[?YXP.U>93_%CX9P17%Q+\0/"=M;VWB4^#;JZ.M:
M3@>*P,?V*Q+ ?V^<C]WCCDA2!@=1XPUBW\/:!K/B6\X@T'2M3U@GU$&ED$?C
MAQQZ_G_+W9_!_5?V@_@_^S_\.=*N-;\->)_CO\:_C)^U3>WEI9ZP,:IX%_Y$
M7@X&!_\ 7KHPV&^M^F^OX_(\?,LR^I_UO_3/Z4O$?Q8^&'@R+6;OQ?\ $/PG
MX;@\,6BWGB3^V?$>CZ<-#76&)0ZRI8!!NR4;C)P^""K&WX!^(_P_^*.B#Q%\
M,O'WAWQ_X?\ M1M?[6\*ZUI.K:8",;AYFA$\@D;=S#(!8# 8C^6/4OBUX<^+
M6@V_Q&_:3@N? &C_ !D_:H\!?#'XDVGB*SUG^S+#PO\  O1?^)[TZ>'?^$CX
M_P#U9K]4OV"=+^'FO?M&_M#?$O\ 9V\.W/A+]FR\T?PQX8T8VEEK7A[PQXY\
M?:(#_;VMZ%HNO"(E4#% ^U"006 +$'OQ.7<JU;LEKI^B]=OOZL\#+.),9C'_
M ,BBW37>SOK?RZ_D]C]AO^FW^D]??KT_^QZX_G7.:-XO\*Z_+J]EX<US3]9N
M-!O!H^LVNE7:Z@="U3:<(_H5SDCC! YZBOR&^%7QZ\7_ !'^.?B_5/'WQ[\6
M?#CQ?X7^*OCO1?#G[/>E^'"WAG_A O FD%UUGQQD-QXIRS1^)\A4PJH%&-OP
M'X;^*?[1>D$:5\.?$=M\'-(^/&L?%'XSCQQXAN]9\-_V]XH/C77]"T/1!KGO
MQGPM[#TQ6&&RWH=^*XC6%WU_K^OZO?\ J8P/]?CCU_3_ .MU]_>F^7/#$/.!
M(]\  ?7\?UK^>?X[_M8_M!Z9XX^'/@C0O&OBO0_BUX/UKX->#?&6EZ0JZ9X'
M\7ZMXYU@)KFMZ+H8Y\1>'@@5 22=H"YVX [#XA_'?]J6T\$?M/\ [17A#QOX
MBU/3_!WQ4TGX3?#;P/:V8/AG0=+C/A[0O'/C;6P<GY/$O]M$'^ [2,'%=']G
M.Z^&U];\UWVZ[_TCGP_%N#>V4-:]D_7>_P#78_?'@?O^/K^A^OH>??WKF;/Q
M;X;N]=O_  O9:YIMQXETRUBO-6T$7BMJ.CZ;* BL54%@"Q4!B0"3DG !K\'(
M/CM^U-X(^%>GV/C#X[:)<>!_B/\ &S3/A]H_QM\.WA\:^)/AKX7=B^OG7-9'
MAP+N9B3X);;O)).>>?I[_@FCI%_XC\6_M6_&&^\8:G\2;;Q#\5M,\$^$/B%X
M@LO[/U+7?"W@6.0@L,<C.M #N20IX-<SR[ZFG?IV>_\ 7]>?1AN(UB\9]2P?
M_#:7\[_KV/UKAM)A%R?P/4CV_P C/IVK1\CW_7_ZU$'?\?Z58K@/J#.ELP>?
M\^W/\S^ ]*7[(/-SGMGVQ_\ K[_KFM"BN<"OY'O^O_UJK_8_;_QZM"BN@#/\
MCW_7_P"M1Y,W_/?]1_\ %5H44 9TMF#S_GVY_F?P'I1]EE\O&1GKCO\ GZ8X
MQU]JT:* ,_['[?\ CU'V0>;G/;/MC_\ 7W_7-:%% %?R/?\ 7_ZU5_*F]/T'
M^%:%% &;]EFQD3F#']W'^..WY?H[[(/-SGMGVQ_^OO\ KFM"B@#/^Q^W_CU'
MV0>5C/;/OC_]7?\ 7%:%% %:*+$8'J/P_P <?J*LT44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% #'Z#Z_T-?*OC_\ 8J_9
M/^*GBR_\;_$;X _##QKXOU,?Z9XA\1^&=+U+4[_"\DR2*"WJ6;D]3DFOJVLV
M74;&%_WM[;)[&Z Q]5''/Z<B@#XW_P"'=/["_P#T:M\%?_",TC_XFG?\.Y_V
M&/\ HU7X._\ A&Z/_P#$U]B_VSI7_02L/_ N'_XJC^V=*_Z"5A_X%P__ !5
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M&K_!G_PA='_^-U]C_P!LZ5_T$K#_ ,"X?_BJ/[9TK_H)6'_@7#_\50!\<?\
M#N?]AK_HU?X,_P#A"Z/_ /&Z/^'=/["__1JWP5_\(S2/_B:^Q_[9TK_H)6'_
M (%P_P#Q52P:A8W@_<7EK/W_ -'N48_3Y'!_,_UP ?&?_#N?]AK_ *-7^#/_
M (0NC_\ QNG?\.Y?V&O^C5_@G_X0>C__ !%?;%% 'Q/_ ,.Y?V&O^C5_@G_X
M0>C_ /Q%'_#N7]AK_HU?X)_^$'H__P 17VQ10!\3_P##N7]AK_HU?X)_^$'H
M_P#\11_P[E_8:_Z-7^"?_A!Z/_\ $5]L44 ?$_\ P[E_8:_Z-7^"?_A!Z/\
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M<;'1-&L+C2[0:?975EI$>G_8=+(XTK1]H&S[IX4[=ISLW$!.VHH \QU/X8>
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M\G_7_:>?^70X-_\ SY_S]4\Z#_GN/^G/_)_SZ4 >T_\ #1'[1O\ T<+\8O\
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M5:5O,T)SO9)0@"K\KC*YFZ#G/TMHK/A_U7_+ST[?Y_/VJQ0!8HHHH ***KT
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MC;4_!]W_ &59>#]6U;^V=2QU_L+_ (0?0_4#_H4\^F:[@_ ?]J^;Q;;Z'/X
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MEZU_PI&[_L;3/ U__P A\_V+GG_A'_\ A$_T_6OPW\7_  -_::TZ'P/8^/\
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MR_#_ .U.<^^/&'[!_P"R?\/?VI;?]GKP=8^)--M]4^">J>--8\;W?C'^TO\
MB:?\)IH&@_V+S_\ 6_I7R/\ M.?LB_LR^%? ?CCQ5\.?$5M\);CX2?&S_A4@
M'BW6-9\2Z9X\TO\ L70->_YE[_F8O\^]?*WA7]F_]K[XM>-_!^JZKX<^)&FW
M'QDU@V6C_$+Q9>:SINF7_P#;O_$^R?\ H7_#O/:O(/C!\,?C%\'_ !1K'@?X
MN:5XDT34+76-4'_$VO/[2\,Z]_87_$A_MK\O<?F:YSH/)^?-_<3_ &FW_P"?
ML]1[_P#U^/7ZE%% !7TA^R7^UI\</V)_C3X7^._P(\1W.F>*-*_T+Q)X>N[S
M_BF?'FEY_P"0+KGX^_;FOF^NY^&/PQ^(WQL^(/A?X5_"3P;J?C;X@>/+S^Q?
M#?A[2;,:E_W&M<S_ ,B_X=_R:YP/]0G_ ()R?\%)/@E_P49^"FD_$7X<ZK;:
M=X]TQ?L7Q&^&=U=_\5)X/\2KY8:.1/,)?0I"TC)*JX"C8Z@H#<?H]7XH?\$=
M?^"2G@K_ ()S?#.Z\4>*IT\5?M+?$W1=-/Q3\5P8.G:,56,_\(?H #@K!$T@
M61F&\R< (@1IOVV$4$(SC\"<\=/;_(]J] YS\HOB'^W]KGPZ_P""E>D_LE^)
M++PGH?P2MOV8O%'[0'C#XB:I?M8:EX>.@%UW:RK'8F@J"06" AL!MX4"JOP?
M_P""Q'['?[3-U\3/!O[.7C?4_$_Q0\'_  Z\3_$+PGH/BWP;XO\ !&F>/?#&
M@(S?V_X*UO7O#D2:_H+2A,O'$3N(7RU3YXOE/]NK_@G1\=?VK/VX/B/XO\/'
M2O#7PA^)'[!_Q _9^7X@+>'^U-#^)^N$G0O[:T'[S>'@N"^T'YB?7G _8N^$
M'_!32W\.W'P0_:&_9?\ V7_A/\-O@[^S-XG^!/AKX@^![G1M4\<_&?5/[$70
M-!UG0]<1<_#[PUD;CX8D)"EB2X4*% .H_89_X+S_ +-'[1'PP^$=E\9/$9\)
M_M#>-_ ?CKQ/<^$M \.ZT?#E[JO@6"?5?$'@_P /^(B#H&M>*C#I;+_PCT4H
ME8 QEU5I"_S5:_\ !QKI/C/X#_#WXZ>'?AE<> /#]S^V5'^S_P#%/_A/M+U9
MAH'@)H]<9=:T(PG;KWB,+H@5XQ@QL&CD1'5T#?@]_P $M_VD?!/P0_X(S^#[
M[X=>"--\3_L@_&'Q1XR_:$-I?:-_:6@Z;KFC[#K&AZX3CQ V[Y2HYW84^WE'
MA7_@F3^W9>_#KX8? #QO\'_AK_PA'P1_X*<?\-'Z1XL'B;1=3/COX-Z[K?B'
M7?[:US0ADCQ%X3.M:*.WW3Q\K"@#]FO /_!9/]@OXA:+HNO>'_B=J=M9:[\:
M]+_9]OK/Q!X3UKPYJ6@_%'7B3H.A:[HVO1Q/HB>)<D1%QN8$O(OFG?7OGB+_
M (*!?LM>#_%O[1_@_P 1?$BVT:3]DSPSX<\2_'3Q#JMK-'X6\(:?XA61]&T@
MZ['N_M?Q)(2P;P^BF8-(1DLV&_G_ /VU_P!D?_A3.E_\%GOC?^T)JO@#X+?"
M_P"//C#X-?$W]EKQPE\IU*\^)_PIT+0GT%FT(D$^(3XDT(*-HW?.K;=NXC8_
M9[_X)O\ QY_:U_X(R>-[CQOKUKX:_;._;0\=>&/VMO&6J>++$G3/$'BK0];3
M7O 7@WQOHV>/#JA7!7!W;PQ*[0& /UX^"_\ P6._8&^.?AGXK>+_  U\7;CP
MYIOP=\-OXT\>1?$#P=XP\#ZK;^ G#'2?&NBZ-KVA0S:[H%P"5CEMD9DD8O(F
MU03YI\3O^"NWPAUW]ES]I;XP_ '4KO3_ (@? CP!IWQ!&F?&/PCXR\%:5=^&
M-=VIH?C)0WA\OKGAZ0,V/)7;A&WLK% _YMZ3_P $]/V]/VOOBCKW[1?[6'[-
M7[.'P=U?X3_LR:K^S?\ #?\ 9]TGQ(/$GA?X[?VZ- _MS6_'>O:"0/#_ (=9
MM$5/ RC+^#&<$+M5W7P?PA_P2:_;D'P&_;B\$>"/"/B+X6_#;XK_ +-__"L?
M W[./Q9^*H^+.I7OQ/Z_VWX)\<GPV!X>^'>,G_A%FQ@<T ?N]XO_ ."K'[.G
MP4\/_!JR^,?B?4]1^)WQ&^#_ (7^+>O>%/AAX0U[QO+X?\":\MO_ ,5OX@T7
M0]"F\1:-X?63559&D@7;C;ALR/+]=?$S]K/X._"S]FW4/VL->\07VH_!+2_!
M^F^-KOQ+H&BZIJ3GPKK$B;=;71%A_P"$@V_.-JE V&Z;@Y7^?#]NO_@F?\?/
MBGH/P U;P[^SV/%?C_P7^S#X7^$UK\9?@]\8!\-OB]X"^)V@Z)_8)T;QRS>&
M@/B!\%QU/A?. .O6OV[_ &:OV<?B-I7["'@7]FG]K#Q)HOQ1\?S?"#4O 'Q1
M\0Z3:?V=I>O/KB3Q.P!QM!67:>>67D8&6 ,3XI?\%-/V2_A+%X$F\5^.-2NA
M\2/@7JG[1_AI="T75=27_A3.B:*-=D\9:UY2J-"C*?*GFAI-P_>,0%QLG_@H
M#^SM>>*/@%X T+Q-?W/B[]J/X6>*?BW\#-/NM&UA8_&'AGP5HHUV9Y<*1HC/
M&0-LBG=@;B,AE_"O]D;_ ((U?M7Z#\'/V_?!WQ[\6:!<^-O%'P5\4_L>?L5Z
MO=WPU,^$?@'LD_L$ZSSU\Q="!+<;1(>HX/V4?V./^"HFO?M0_L'^/OVH?@G\
M*_AO\./V0?V?/BG\"K.Z\)>/E\2ZKK^K:SHG]@Z-XS !)T ^*>-X&=N5# 9K
MG,;O^KGV_P#LU?\ !:SX93?L<^'/VFOVPI[;X;^)?'7QY^*'P9\"^"/!.D:Q
MXW\3>+V\"^,CX?!T31-!1G=NF6,BG[IR_P PKZ5T?_@K_P#L/^+_ (3>)?C%
MX'^('B3QQH&@?$C_ (5'9:9X3\">,]0\4>*_B?Y)UG_A#]#T!?#1\0R2D[0"
M8HT5&( ^4!OYKO&'P(^-'_!,/P9^P?\ &+XF3_!2V^/WPP^.W[6=GH_P?^,6
MM?V;\,?%W@+XL^,SKW_":+XZ'AS_ (1KP]XC\)>&]<!W8 ^8;23D+C?L3_#K
M]O/]I3]G_P",_P 2OV;8=,\-:3XS_P""CWC[QO\ &NS^"5YHWAK4_%WA5#KB
MNW[.7CCQ#X;QX?"F1 ?%/^USZUT&Q_33XA_X+%_L(^'OV8K']K[7OB?J>G?!
MW_A:#?!75[IO".OGQ#X4^*;AE?P5XA\/#0QXBT77\'/EO$H /RN3G;XU\.?^
M"P/PR\;_ +0GQ>&N>*O#/@?]EKX;?LWZ5\=KOQ%XW\-^-?!7Q*TW3#J_EOK>
MLZ#KWA^,KX>,9=%92"I8MC.X-^17PP_X(_?MG:%^Q%/\ O$7@/0=3U\_\%4_
M#7[4UW:^(/&2^)!X@^#R?V'YFKZWKF3_ ,)!XD0QN'4<IY;YQM('Z,_'W_@G
MQ\>/B/\ MW_MG_&+3/A5\+O&WP@^,O[#?A;X+>$/#OQ!NV;PQXL\5:&<'1-<
MT,*K: H/&\JH"C<P49PL2DDTMM>M^X'Z6_LL?\%!/@#^V!KGB?PG\*[[Q9IO
MB_PMHNE>)KWP_P"./!VM>"M4U#PMKN?[%\9Z$NO>6-=\/NO\:<%CG854 _=D
M4H(_7C_/YC\17\U?_!)#]@7]J3]F+]ICQQ\0-8TGQ9\%/V8+OX6IX,M/@/\
M$WXD+\;?$P^)G]N;I-:\#^.3H$/_  CWP\:,.B>&=Q\N1D=E=%93_2M#_J1]
M#_*L )Z***Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O\ ,/\ ^"_T/_&UG]HB =/['\+_ )?V+P/\
M?TK_ $\*_P P_P#X+_:E!#_P5>_: \^?[-_Q)_"_0_\ 4%^G'/T[\4 >;_"7
M]O;PM\,/A3\-_#FN>!_$GQ:\<?"^\TN]\!VGBR\T;_A&?"7]A:T#_P 2/_YE
MO%F<5[!XD_X*<>!_%7A+XH?"N^\&_$BV^&_QDO-4UGQAXA\/7FC:=XY\)>*=
M=UK^WO\ BA_7PZ?\.*_%?^U]*_Y[CR/I[8_S[\]*/[1LO^>WZG_&CZSY_C_]
ML!^S&F_\%/O"NFVOA?P=8>!_'_\ PK_2_@_XH^$GB6[\0^)1XD\39U[6M UW
M^VM#_P"$@'_(Q9T/K[?@-CX>_P#!5#P=X5O_ (P3^(_ 'C;4O^$R_LO_ (0.
M[M-8_LW_ ) 6BZ!H)_X3C([?V%Z>G<5^)\.L:5#%_KQ_GV!^N?QZTG]IZ7_S
M\6WZUS_6?/\ '_[8#]L? ?\ P4L\.:]\4/B!/?>'+G1-'^,GCS2M;L]6\;ZQ
M_P 2SP'IFA>"_P"P==_L/_H7_$9XZ?CZUY?^T5^T5\#_  W\9/V+X/ &J^)/
MCKX/_95\!_8O&-YJ^L?VEJ>O:IKNM>(->_Y#GO\ VYZ^PK\G_P"TM)G_ .6^
M<<?:^GZ?A^&?Q!_:6DX^S^?_ */_ ,^G^1ZT8G$G0?NQXV_X*K?"3QY\+[?X
M.^(_AS\2+GPO=:Q_;6L^++2\T;3?$W_$B\:?V]H6B]/^$8_X1WTYR>OO5?QA
M_P %;O &O6NL:'H?PD\;?\(_=?%32_CK9CQ#XD_M/4[#QYH7_,E^_P ._P#A
M'/\ F5O^ATX]J_"_^TM*\K_7\=??T_/]<^U$VI6/7S[;^F?\,=/3OB@YS]F/
M#?\ P4L^&7@_P;XP^&5CX ^*.M^#_B-XPU3XG>)/$.K>)/[2\<Z#XHUW6M U
M[^Q="SQ_PCO_ !(ZQM2_X*6^%=>\6ZAXQ\1^!_B1]H\+_&S5/C1\*])TGQ)_
MR'M4UW1?[!_X0OXJ?]#!X=_S[U^0']HV7_/;]3_C1_:>D_\ /S^G_P!>@Z#]
M]_$G_!2WX._##X@_#?XJ>#K'Q)\4?'&O?L]Z7\/OB1X3M-8_XMGX2_XG7]O:
M[_8>AY_Y&+\*_,#X_?M%6/QL^'/PG\#_ -A^)+;4/ASXP^*'B:\\0ZMK']I:
MG?Z7XZUK^WM"T7G_ *%,'I_^NOD?^TM*AY\_I_Y(>_\ G'X\4?VEI4/_ "WM
MB.GOGV^G^/UHQ/7Y_P#MP&AG_IO^G_UZ*S_[1LO^>WZG_&O2/A+\-_'_ ,>/
MB-X7^$GP=\*ZEXV^)'C+6/[%\-^'M)L\]O\ F-\'_BG?SH /AC\,?B-\;/B-
MX7^%?PD\*ZEXV^)'C*\_L7PWX>TFS_M+(^O_ $+O;O\ RK_1L_X(_P#_  1_
M^'/_  3J^'T?C+Q=#I_C;]ISQI:*?'?CB<1R+X55T)_X0_P8<'R[1,@O(K([
M, %*J )G?\$@O^"/_P ._P#@G7\.X/&?C&#3_&G[47CC2%/CSQT+6';X75HV
M9O!_@HG<8[6/.3)E9&D1L#RU'G_MS!%-$,S$$=.H]?7G!/Y?RKH.<LPP^5_G
M_/'7O4K]!]?Z&GT4 9WV67S,Y&.N?_K>F><=?:E\G][_ )SU^N.O?],5H57K
MG K^3^]_SGK]<=>_Z8I#: 1SC^]G'.,XY_#'ZUHT5T >3?$'X0_#?XPZ'#X=
M^*/@'PKX^T"UU;3]:LM)\::+I/B+3AJVBG=HVM"*564R*0&175F!)7:J,P;T
M(:?##;06=O"MO;0*+1;>W;"BPQM"XZ@$*,XY^\,DDUKT4 9_V/V_\>H\CW_7
M_P"M6A3-@]3^G^% %$6@CDR.1^'3V]#],^_K0;02CG@?G^&/?.<Y]JL^1[_K
M_P#6H\CW_7_ZU %?['[?^/4GV.#'[[!_'C\^?R_'TJSY'O\ K_\ 6JQ0!XS\
M6?@?\(_CAX?/A;XQ_#+P5\4O#ZG[5;:3XW\-:/XETZR8=6$>N*^2W4X"X'7@
M8KI? W@'P;\./#EAX*\ ^%/#O@CPEH<:V^E>'?"6D:;X>T:P4+P(M(T18H5S
MD$@!"P^9U!^:O0:KUS@5_L@\K&>V??'_ .KO^N*)[3SH\9&?\_Y'/)]*L58H
M S_LG_3;]?\ Z]7(XQ&,#_/L.^*DHKH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **S]1U"WTRROKZX(
M\FPMGNI\=0B*S?J$/7VKS#_A='@[TU/_ , ?_KT >KS]OP_K7SGXO_9/_9L^
M(/B*^\8>/O@7\,?%GB_40!>^(/$7A#1=5U34 H !9I-[EL=3NW'DDDG-=G_P
MNSP?_P!1/_P#;_"C_A=G@_\ ZB?_ (!M_A0!YG_PPW^Q]_T;3\&/_"!T+_XQ
M2?\ #$'[(/\ T;3\%?\ PW&@_P#R/7IW_"Y?!/\ >U+_ , 3_P#%4O\ PNCP
M=Z:G_P" /_UZ /,/^&(/V0?^C:?@K_X;C0?_ )'H_P"&(/V0?^C:?@K_ .&X
MT'_Y'KT__A='@[TU/_P!_P#KT?\ "Z/!WIJ?_@#_ /7H \P_X8@_9!_Z-I^"
MO_AN-!_^1Z/^&(/V0?\ HVGX*_\ AN-!_P#D>O3_ /A='@[TU/\ \ ?_ *]'
M_"Z/!WIJ?_@#_P#7H \P_P"&(/V0?^C:?@K_ .&XT'_Y'H_X8@_9!_Z-I^"O
M_AN-!_\ D>O3_P#A='@[TU/_ , ?_KT?\+H\'>FI_P#@#_\ 7H \J_X8@_8_
M_P"C:/@K_P"&WT+_ .,T[_AA_P#9$_Z-I^"O_AM]"_\ B*]3_P"%T>#O34__
M  !_^O1_PNCP=Z:G_P" /_UZ /*_^&&_V0O^C:?@I_X;G0O_ (FI?^&(/V0?
M^C:?@K_X;C0?_D>O3_\ A='@[TU/_P  ?_KT?\+H\'>FI_\ @#_]>@#S'_AA
MO]C[_HVGX,?^$#H7_P 8KI_ G[,/[/?PM\0MXI^'?P8^&'@GQ2UG]A_M_P .
M>$M'TK4UTS^Z)8E5P W!;.<<'@[:Z;_A<O@G^]J7_@"?_BJ3_A=G@_\ ZB?_
M (!M_A0!ZS!W_'^E6*\@_P"%T>#O34__  !_^O1_PNCP=Z:G_P" /_UZ /7Z
M*\@_X71X.]-3_P# '_Z]'_"Z/!WIJ?\ X __ %Z /7Z*\@_X71X.]-3_ / '
M_P"O1_PNCP=Z:G_X _\ UZ /7Z*\>_X79X/_ .HG_P" ;?X5#_PNSP1ZZW_X
M*/\ ZU 'L]%>/?\ "[/!7_41_P# (_\ Q5._X71X.]-3_P# '_Z] 'K]%>0?
M\+H\'>FI_P#@#_\ 7H_X71X.]-3_ / '_P"O0!Z_17D'_"Z/!WIJ?_@#_P#7
MH_X71X.]-3_\ ?\ Z] 'K]%>0?\ "Z/!WIJ?_@#_ /7IG_"Z/ O_ %%/_!4U
M 'L5%>0?\+H\'>FI_P#@#_\ 7IO_  NSP?\ ]1/_ , V_P * /8:*\@_X71X
M.]-3_P# '_Z]'_"Z/!WIJ?\ X __ %Z /7Z*\@_X71X.]-3_ / '_P"O1_PN
MCP=Z:G_X _\ UZ /7Z*\@_X71X.]-3_\ ?\ Z]'_  NCP=Z:G_X _P#UZ /7
MZ*\@_P"%T>#O34__  !_^O1_PNCP=Z:G_P" /_UZ /7Z*\@_X71X.]-3_P#
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M>0?\+H\'>FI_^ /_ ->C_A='@[TU/_P!_P#KT >OT5Y!_P +H\'>FI_^ /\
M]>C_ (71X.]-3_\  '_Z] 'K]%>0?\+H\'>FI_\ @#_]>C_A='@[TU/_ , ?
M_KT >OT5Y!_PNCP=Z:G_ . /_P!>C_A='@[TU/\ \ ?_ *] 'K]%>0?\+H\'
M>FI_^ /_ ->C_A='@[TU/_P!_P#KT >OT5Y!_P +H\'>FI_^ /\ ]>C_ (71
MX.]-3_\  '_Z] 'K]%>0?\+H\'>FI_\ @#_]>C_A='@[TU/_ , ?_KT >OT5
MY!_PNCP=Z:G_ . /_P!>C_A='@[TU/\ \ ?_ *] 'K]%>0?\+H\'>FI_^ /_
M ->C_A='@[TU/_P!_P#KT >OT5Y!_P +H\'>FI_^ /\ ]>C_ (71X.]-3_\
M '_Z] 'K]%>0?\+H\'>FI_\ @#_]>C_A='@[TU/_ , ?_KT >OT5Y!_PNCP=
MZ:G_ . /_P!>C_A='@[TU/\ \ ?_ *] 'K]%>0?\+H\'>FI_^ /_ ->C_A='
M@[TU/_P!_P#KT >OT5Y!_P +H\'>FI_^ /\ ]>C_ (71X.]-3_\  '_Z] 'K
M]%>0?\+H\'>FI_\ @#_]>C_A='@[TU/_ , ?_KT >OT5Y!_PNCP=Z:G_ . /
M_P!>C_A='@[TU/\ \ ?_ *] 'K]%>0?\+H\'>FI_^ /_ ->C_A='@[TU/_P!
M_P#KT >OT5Y!_P +H\'>FI_^ /\ ]>C_ (71X.]-3_\  '_Z] 'K]%>0?\+H
M\'>FI_\ @#_]>C_A='@[TU/_ , ?_KT >OT5Y!_PNCP=Z:G_ . /_P!>C_A=
M'@[TU/\ \ ?_ *] 'K]%>0?\+H\'>FI_^ /_ ->C_A='@[TU/_P!_P#KT >O
MT5Y!_P +H\'>FI_^ /\ ]>C_ (71X.]-3_\  '_Z] 'K]%>0?\+H\'>FI_\
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M6\/BUH];_P"+\6MOO_,6'SG*<7'ZY&5NEVE>_H[.Z>GE9]CTS[%9?\^5O_X
MC_"H/L-E_P ^6G?^ :UYYH?Q3^&GBK6=7\.^'?''A/7/$6E?\A;2M(UG2;_4
M;$G^^@)SV/S!@,=1BI?%WQ+\$>"[BPT_Q'XM\/Z-J^J6S?V/IFKZQ'IM_K3(
M-N%#%9&R1@,J,-Y;)4 @8?5\7W_]*_R.G^T<'OV_K^OR.^^QV/\ SX6W_@%_
M]>I3I]GG_CTL?PLX@/Y#]:_._P#9 _;BL?VA/!'Q \8^/M)T3X76_@WXOZQ\
M)M'-UK .GZZ^A]T+D@,07'(P,@9 !5ON&?QQX0TWQ%I_A6]\0Z-;>*-=M3=Z
M1X?NKM1JE^H!^=02Q89PH&-QR64,,;EB<-BUM^O;SO\ F+#9E@\7JG^"?X.Y
MU_V&S _X\K ]\FTBZ=>H!JN4L1PUM;#U(M%P/QP#^5>>:I\6/AIH'B6Q\'Z]
MXY\*:7XJU52;/0-0U?2[/5+X@=/):178\9"@@GC ;H?F;QG^W#\+O!G[5/@?
M]EB\GM3XJ\3^&=3\2:QJUWJ:IIVA['/]CZ,?GE!UZX*A@G!6,C)W'*O#8;%^
MM^G73?K^I,LXRFW^URMKU2=N]]7^9]NK;60!S#;G/K:@D?\ CH_K4,4-B)#!
M]BMA@=?L@X_$Y R.O]._AO[3'Q?F^ GP&^)_QATS2H-;N/ ?@_4_%%KI5PS+
M]O*D'&5(;!.#@=0#G()!_)"#_@IO^V5X:^'.C_'SXB_L0D?!"ZTC3=<UGQ9X
M2\8_VGJEAX8;);6_[#;/&6R!C X  7 .^'PS?]?CV.+,L[P>5?[&_GIT^7^1
M^]/V&R_Y\M._\ UJ8V%EWM-/'_;H@_H*\+\(?'[X7^*?A-X8^-$/BG1=.^'W
MB?P]I>N6/B'5+M=.TUH];4$!VD( 8OQUSW!QEAU9^+GPS@T#2?%<_C7PK#X9
MUVZ^R:/KW]KJ--U#4V# (CDK&3E2"#(-N06(5E)3PV*7?Y<__!^[?0[\/F.#
MQ>S7X-?U_P $](^QV/\ SZ6__@$G_P 31_9UG_SZV/\ X"1_X5RFK^//!_AR
M[\/Z?KOB'1-(O_%5X;#P[:7=W&#K6HE<^7I(:0[S\QX5<;3D@<%L*Z^*?PTB
M\4CP/-XZ\)?\)IL!'A)O$6D_VP<CJ=&:3<".^8]P/4YK#ZMY?A_P#?ZWA>]O
M1+];GH?V&R_Y\M._\ UH^QV/_/A;?^ 7_P!>OA'QM^UOKOAK]M[X4_LI6_@[
M3I]#\>> =8\:7?C>XO&&H6#:&23I BW%"S-\P)!9L_>^8Y^HM2^+GPYTCQ/8
M^$-5\>^%=-\7ZFNZR\/7>KZ0FJMC/ B)#YXP PR>P.0:W^K>7X?\ X?[9PG=
M[VWCO]Z_KYV]*-E9,.;&W7Z6A!_'''^>E LK)0<6-NWUM"3^&>/\]*XO7O'G
M@WPY?6VE^(?%&B:1J^I6S7=E9ZKJZ::;W3T)1F!D91\K!E; )SG&1D"CI'Q:
M^&>MZ!?^,-%\;>'=0\+Z8#_;&OVVKJ=,L".FYE+JN<\#<.>AK'ZOC.^GH_\
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M:C^SK#_GRM?_  #_ /K5I44 9O\ 9UA_SY6O_@'_ /6H_LZP_P"?*U_\ _\
MZU:5% &;_9UA_P ^5K_X!_\ UJ/[.L/^?*U_\ __ *U:5% &;_9UA_SY6O\
MX!__ %J/[.L/^?*U_P# /_ZU:5% &;_9UA_SY6O_ (!__6H_LZP_Y\K7_P
M_P#ZU:5% &;_ &=8?\^5K_X!_P#UJ/[.L/\ GRM?_ /_ .M6E10!F_V=8?\
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M . ?_P!:C^SK#_GRM?\ P#_^M6E10!F_V=8?\^5K_P" ?_UJ/[.L/^?*U_\
M /\ ^M6E10!F_P!G6'_/E:_^ ?\ ]:C^SK#_ )\K7_P#_P#K5I44 9O]G6'_
M #Y6O_@'_P#6H_LZP_Y\K7_P#_\ K5I44 9O]G6'_/E:_P#@'_\ 6H_LZP_Y
M\K7_ , __K5I44 9O]G6'_/E:_\ @'_]:C^SK#_GRM?_  #_ /K5I44 9O\
M9UA_SY6O_@'_ /6H_LZP_P"?*U_\ _\ ZU:5% &;_9UA_P ^5K_X!_\ UJ/[
M.L/^?*U_\ __ *U:5% &;_9UA_SY6O\ X!__ %J/[.L/^?*U_P# /_ZU:5%
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MM-_\*4?XT?\ "P?C#_T2K3?_  I1_C74?O?\[J*#H.7_ .%C?&'_ *)9IO\
MX4@_PI/^%C?&+_HENC?^%(G_ ,374T4 <O\ \+!^,/\ T2K3?_"E'^--_P"%
M@?&/_HEFB_\ A2+_ (UU5% '+_\ "P?C#_T2K3?_  I1_C1_PL'XP_\ 1*M-
M_P#"E'^-=110!R__  L'XP_]$JTW_P *4?XT?\+!^,/_ $2K3?\ PI1_C744
M4 <M_P +&^,7_1+=&_\ "D3_ .)H_P"%C?&+_HENC?\ A2)_\374^?[?I_\
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M=2^$^J7GVWQ)X3_Y"6I^ ]4Y_P")SH>?^9='^?8 ^MO^$KTOUN/^^1_C3O\
MA)M)_P">]Q^5>;V=Y8ZE86^JZ5?6VI:/JEG]MLKNT_Y?]+X['MVS_P#6(L4
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M/RKHX7$T4<HXW#/KZ@_KS7CE>M:=_P >-G_U[I_): +U%%% &9?_ /'A??\
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M&J>'/#OC;Q;\./"_@/Q/9WMU\3?@_P",?BT=/!\%Z !_PM3P-X?Y_P"$A)!
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MNI?;]+S_ ,AK/_0N\?U^BV>L:5J5@-5TG5=,U+1\'_BH;2\_M+3/PUSMZ?\
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M<\+_  P^&_Q#NQ_9WACXL?V#X);0]"\:Z+KF<+XA\6%=H/7<RCO1]6\OP_\
MM3H/Z =-\5>#M>O]8TKPYXQ\)>(]8T'_ )#&E>'O$FC:EJ=CT_Y#FA#G\\?A
MQ6Q!W_'^E?SN_L.6<&@?M<? #0_@[^QKXC^']AX8^%>J>&/VCOBQXM\->,O#
MGCG0?'N/^)[_ ,)QK>OD>&?B%_PE?B,9\$^)\@GG!' K^B*?M^']:#G/#M?T
M'5?ACJFH?$;P!8_VEX?U3_DI'P\_Y_\ _J-:'^9Y],UG65[#X)MF^)OPZFN?
M$?PF\4$7OB[PI:$'4_"FIE03K>AXY!!R"#Z @G.![5XK\5Z7X)TNX\1ZK/\
M9K>U_P!"L[0'_B9W^J?] 70^OO\ YZ^#>&YO^%5V'BCXC>(])_LW4?BA>?\
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M'6L>*M#^$.@V7P?\8^&M.\<ZH5;^W/BC\4/&SHZ>(6\5MM'@=7!4 98MC:^
M']"<.IZ5_:MQH7]JZ+_PD%M9_;;SPH-7T8^);#3.?^)R=#'3@<D\'( ))P>/
MO/B=\,M,UG_A'-5^)O@#3?$&?L5YX>U;QAHVFZG_ &H<?\P/O@^M?S?>"(OV
MT='_ &XM'_X*'ZI^S9XFTWX?^._V@]2^$OB35[75VU/QS_PH;7LZ!H/]N?"X
M\:#X>\)>(QHA;Q0&+#(+@!E+?H?\=_V1?A+XO_X*?_LS_$:_^!&B>)M(U3P%
MX^UKQYXW.D#^R_\ A*="R=!UC7"%'_%0C.T$C)P-V2<D.?ZSY_C_ /;'ZM0Z
MSI4TMQ;_ -K:;_Q*S]MUC_3=%SH6E\\:YS_Q3_Z\#TJMHVO^'/$NESZYX=\4
M^'/$>CVUW]CO-6\/ZOHVI:9I^,9!(RH//'/)SC.":_!#XY?"3X[Z]?\ _!3#
M_A%?!'Q(U+1]>^/'P'\3ZQX>\/?VSINI_$SX-Z%_R/6B^!_^Y<].O->D_L>>
M&=-OOCU\=_B-^R_\&_B/\#?V4;G]FG4/#5WX(\:>$]<\!Z9XL^,*Z8I!T/P3
MKVYMR1<R>)?]7<$/"X$4K !T?6?/\?\ [8_:^#6-#/\ 9UQ;^(_#=S_:H_XD
M]W::QHVI?VZ?^H&#_P C!VXX_*M#_IAY%M<VUW_RZ?\ /_T[^GK[]<]*_D<_
M8\^ 7[7WP8^./_!.GP?XB\)_$KQ-^SAKOQJ^,OQI77]>L]6_M7X$^*=<UG.N
M^"?&Q9E3_A'_ !:1_P )."[*H)&YE&37]<<W^M_Y^;<^MGT'\O\ .?2N@#Y_
MU*SOO@;?W'B/0['4M2^$^J7GVWQ)X>M!_P 3/P'JG7^VM#_ZEWT].G%>\:;J
M5CK%A;WVE7UMJ6GZK9_;;.[M,#[?_7]1VKE_&WC;2O!^E^??0?VEJ&O?Z%H_
MAZT/_$S\6ZKQT&/^1=]<=.@]*Y_X5^ [[P'H.H0:K.?[0U[6-4UO_A'K3(TS
MPE_;O_,$T/\ ^L*YP/4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KUK3O^/&S_ .O=/Y+7DM>M:=_QXV?_ %[I_):
M+U%%% &9?_\ 'A??]>6I?^@M7E5>JW__ !X7W_7EJ7_H+5Y50!9A_P!;!]?Z
M"O%_AC_R&?BS_P!CW_2O9X9L2V_7W[]N_3_/U-?._@GQMX5\-^(_BQ8^(_$=
MMHEQ=>//]#M+O_E__P ]/3IB@#Z HK@/^%J_#'_H>-$_\=H_X6K\,?\ H>-$
M_P#': /1Q-/W_P!&M_3V_P _THYA/_+J;<'^7^?<Y],UYO\ \+:^&/\ T/&B
M_G_]E1_PMKX8_P#0\:+^?_V5 'I$,T__ #W^S?:O^G3_ #_D5!Y\\V9Y^3_T
M]\?7V_E^5>??\+4^&?\ T.>A_F*/^%J?#/\ Z'/0_P Q0!Z1YLWK^H_QH\Z?
MR?L_X]><_7'X8]>.M>;_ /"U/AG_ -#GH?YBC_A:GPS_ .AST/\ ,4?6?/\
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M1^_!^T_\?G_3]]/U],9YZUR_BKQ5I7@_1KCQ'KDX^SX^Q6=G:?\ (3U[5/\
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M_P"%M_#'_H<=$_-: /1O.N/^>X_S^-+#>3^W?C]3WZ#]<_A7F_\ PM3X9_\
M0YZ'^8I?^%J_#'_H>-$_\=H ]'$W_;SVO/\ 0_;_ #^G3 HG[?A_6O./^%J_
M#'_H>-$_\=I/^%J?#/\ Z'/0_P Q0!Z09I_-^T<6W'\AW^OYT>=/_K_^?4 6
M?'?V_P /K7F__"U/AG_T.>A_F*/^%J?#/_H<]#_,4 >D>;-_[>?>'^'Z?I5?
MK_S[7-Q_T]V>/\^M<!_PM7X9_P#0\:)_Y6*3_A:GPS_Z'/0_S% 'I/G#_4?\
ML/U]/\^WMQ58>?-U^S=,8^Q_YY_SU//G_P#PM3X9_P#0YZ'^8JQ_PM3X9_\
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M $!-#[?4?GZ4?6?/\?\ [8"SX)\$WUGJEQXX\;SVVI?$#5+/_0_^@9X2TO\
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M4&\+/^A-QA_X O\ ,_K:_P"$,\$_]"MX8_\ !3I/_P 14W_"'>"O^A5\,?\
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MX<_\%&D__$5-_P (7X*_Z%/PY_X)]+_^-5TL'?\ '^E6*\ _6#DO^$+\%?\
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M ()]+_\ C5=;10!R7_"%^"O^A3\.?^"?2_\ XU1_PA?@K_H4_#G_ ()]+_\
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M\$^E_P#QJNMHH Y+_A"_!7_0I^'/_!/I?_QJH?\ A"O!/_0J>'/_  4:3_\
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MT %%-WKZ_H?\*A\_V_3_ .O7-]87E^'^8%BBJT4H(_7C_/YC\15FND HHHH
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M_P#E]QW9/G.%S5-1;A--J46K6:Z=7W_X:QMT57JQ7OGL!1110 4444 %%%%
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M(@\#6>JX/B:S\-8_=IKPR,/\RE,\A?;%?I>Q9A(BL<X#+G/(_''4<]>/U'\
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MAHGQB_:,\?\ P"_:?M?VM/ ?_#,5I::/\2]2U/\ X4WH6M:!_8.B^!]#\/\
MB3_A&/$'PZQSXW_^L* /[9/@/^V!\%OVCM>^.'AWX::W<76H?LZ?$?5?A?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 4G^Z_P#N1_\ H K^./\ X*3?\GC_ !/_ '^/]"TK(_3GZ>_3KWQ7]C<G
M^L;_ '4_]!K^.S_@I5##-^V/\1_^O+2ATZ\?YZ=O2OV[P*?_ !F45_TZ7_I1
M_ _[07_DS^3?]EA#_P!)/2/AO\#/ASXV_9ST_5M#\ VUM\2-+L_^$GU?Q7XL
M_MC3<ZI_;6?^)'KO_(LGP]Z^%NF,<#!-?0'Q(^%?@'7OBW\.?$=CI0\1W'B>
M]%E\1_%EI>_V=J?@/4]"T4?V%X+T/0L#')(QSP <\X'Y$7FL?%30?!&CV,VN
M>+=-^'_BB\_XD]I]LUG^S+_^PA_G\?>LC_A/?&%G=:A?6/C'Q);3ZI_Q^7?V
MS_C_ /\ ./IC%?O.)X1QF*QGUW^V7NWJ[[][MZ7V2M;;3K_G?EOBCD^$R?ZE
MC>#OZ\ORZGZ3WGPJ^!\UAI_PY_X5SIO_  E'BCX)^*/B=_PL*TO/^)G8:IH6
ML_\ ,#Y^AZCMGUKR_P#8A^#/AOXD6OB#Q3XX\'>&_%N@6OB/2_# N]6_MG4M
M3L-3X'.A^'\=./S_ !KXWFF^)NFZ-H_C&^OO$EOHVJ?VKX8T?Q#]M_X_]+'_
M #!=#'X=ZS_#?C#QCX5BO_\ A%?%?B3PE]J_T*\_LC6/[-^W<]#D#^HY'4YQ
MT_V)C/['SC!+..NM[O3KUT=OE?N?/XGC;)_]9,GQN=<'_P!=#]8)OV:/A7X:
MU2W\.6/P6_X3_3_%'Q4\4>"]8\;_ &S_ )$/PO\ ]!KK^H]_2L[PO^SM\'KN
MS^&/@^;X4G7?#'Q%T7Q2?%_[02ZR--/A0Z#K7_$AUA2Q"@L0 "Q"@GE@,FOS
MPU+]HKXFZE\/M'^&0US6]-T?2[S5+V\U:TO#_:?BW^W>^N>OM]*K^*OC7X_\
M2>"/"'@#^U;G1/"_@W1_^$8_LG2;S_B6:]_V'.WO@>Q'7->/A^$>)'=?VQ9[
M7[/H_P!=='L[IL^XS+Q:\-\)C%_QA_K_ %O]WX,_0_XR_LW_  "TW3]&\*^
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M^%MO\%/LWQ(\=68\#G&%'(_MH8 ."02=Q)R>H7 'YUSL3@0DF88X[8 QV_\
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M &O-K0TO3AJYLQ9G4Q8K_:90#!3^V"N\@YQM4!@>IX(.=-X3\.7FKVWB"_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;_T.?Q0O^)5/&W_HCI?B?F'17Z??\.B/VK?^@CX'_P#!A_\ 7H_X=%_M5_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4S8/4_I_A110!7V#U/Z?X58V#U/Z?X444 &P>I_3_"C8
M/4_I_A110 ;!ZG]/\*-@]3^G^%%% !L'J?T_PHV#U/Z?X444 &P>I_3_  HV
M#U/Z?X444 &P>I_3_"C8/4_I_A110 ;!ZG]/\*9Y$7]VBB@!^P>I_3_"GT44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>form424b3_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form424b3_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !D 2P# 2(  A$! Q$!_\0
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M11P!TSUK?^!_[)'PH_9VU?4]4^'GAG^P;[4;=;:ZD&HW-SYD8;<!B61P.>X
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M%4#DDGL*_%+_ (*2?M\3_'G7KGX=>!-2:/X;:=,/M=W;L5_MRX1LAB1UMT8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
